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A. LIST OF ABBREVIATIONS 
 
 
ASC Adult Stem Cell 
BM Bone Marrow 
BSA Bovine Serum Albumin 
CABG Coronary Artery Bypass Surgery 
CAM Chorioallantoic Membrane 
CHF Congestive Heart Failure 
CsA Cyclosporin A 
DAB Diaminobenzidine Tetrahydrochloride Dehydrate 
ECs Endothelial Cells 
EGF Epidermal Growth Factor 
EPC Endothelial Progenitor Cells 
ESC Embryonic Stem Cells 
FGF Fibroblast Growth Factor 
FS Fractional Shorting 
H&E              Hematoxylin and Eosin 
HSC Hematopoietic Stem Cell 
ISH In Situ Hybridization 
LAD Left Anterior Descending Artery 
LVDd Left Ventricular Diameter in diastole 
LVDs  Left Ventricular Diameter in systole 
LVEF Left Ventricular Ejection Fraction 
MI Myocardial Infarction 
MMPs Matrix Metalloproteinases 
MSC Mesenchymal Stem Cells 
PB Peripheral Blood 
PBS Phosphate Buffered Saline 
PCI Percutaneous Coronary Intervention 
PCLA Poly-L-Lactide Fabric 
PECAM Platelet Endothelial Cell Adhesion Molecule 
PGA Polyglycolic Acid 
PLGA Polylactic-co-Glycolic Acid 
SD  Sprague-Dawley 
SMA α−Smooth Muscle Actin 
UCB Umbilical Cord Blood 
VEGF Vascular Endothelial Growth Factor 
VEGFR Vascular Endothelial Growth Factor Receptor 
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Introduction et résumé  (en français) 
 
Malgré les progrès médicaux, notamment dans les stratégies de revascularisation 
coronarienne, l’ischémie du myocarde reste l’une des causes majeures de mortalité liée aux 
maladies cardiovasculaires. La capacité limitée du cœur à se régénérer suite à un infarctus mène 
à une perte fonctionnelle, un remodelage ventriculaire et, finalement, une insuffisance cardiaque 
(Abbate et al., 2002). Bien que les techniques telles que la dilatation coronarienne par voie 
percutanée ou bien le pontage coronarien ait amené une amélioration substantielle dans le 
traitement de l’infarctus, il reste encore beaucoup de progrès à faire. La thérapie idéale 
consisterait en : 1) minimiser la perte des cardiomyocytes en réduisant la mort cellulaire, 2) 
promouvoir le retour du myocarde choqué et hibernant à une fonction normale, 3) stimuler la 
revascularisation de la région ischémique en améliorant l’angiogénèse et 4) régénérer les 
cardiomyocytes perdus durant l’épisode ischémique ce qui permettrait de préserver la fonction 
contractile et minimiserait la cicatrisation. 
Le retour à une perfusion normale du tissu ischémique est une composante essentielle du 
traitement. Ceci pourrait être facilité : 1) à l’aide de facteurs angiogéniques et/ou 2) par thérapie 
cellulaire (par exemple, en utilisant des progéniteurs endothéliaux).  
1. La thérapie angiogénique: elle repose sur la distribution de cytokines angiogéniques, soit 
par administration directe soit par thérapie génique, qui mène à une néovascularisation ainsi qu’à 
la formation de vaisseaux collatéraux qui forment un pontage autour des artères bouchées (Syed 
et al., 2004).  Le « vascular endothelial growth factor » (ou VEGF) est un facteur angiogénique 
majeur qui agit principalement sur la prolifération des cellules endothéliales en activant le 
recépteur-2 à VEGF (VEGFR-2). L’importance du VEGF dans l’angiogénèse a été clairement 
démontrée chez la souris VEGF knockout, où la perte d’un seul allèle (souris hétérozygote) 
conduit à un développement vasculaire anormal et à une morbidité embryonnaire précoce 
(Carmeliet et al., 1996 ; Ferrera et al., 1996). Après la naissance, le VEGF a aussi un rôle 
déterminant dans le développement et la stabilisation du réseau vasculaire. Cela a été démontré 
par un modèle expérimental d’occlusion vasculaire qui mène à une surexpression de VEGF 
endogène dans le tissu ischémique. Il reste cependant beaucoup de problèmes à élucider, tel que 
la question de l’administration optimale du VEGF. Ainsi, l’injection intraveineuse de VEGF est 
inefficace (Sato et al., 2001), et peut même être néfaste car elle favorise l’hypotension (Horowitz 
et al., 1997), une augmentation de la perméabilité vasculaire (Thurston et al., 2000), une 
rétinopathie proliférative (Aiello, 1997), ou encore l’induction de la croissance tumorale (Epstein 
et al., 2001). Ces effets secondaires pourraient être évités en pratiquant une distribution très 
 6
localisée du VEGF. Par ailleurs, l’administration de VEGF doit être durable pour pouvoir 
soutenir la néo-vascularisation qui est un phénomène étalé sur plusieurs semaines. Or, il a été 
démontré qu’une production soutenue mais non contrôlée de VEGF peut causer des 
hémangiomes ou d’autres malformations vasculaires (Lee et al., 2000 ; Schwarz et al., 2000). 
C’est pourquoi l’administration de VEGF se doit d’être locale, soutenue et contrôlée. 
2. La thérapie cellulaire: les cellules progénitrices endothéliales (EPCs) ont été identifiées et 
isolées à partir du sang adulte périphérique par Asahara et al. en 1997. Depuis, leur potentiel de 
différentiation en cellules endothéliales a été démontré par des expériences ex vivo et in vivo, ce 
qui en fait des candidates pour diverses applications thérapeutiques (Rafii and Lyden, 2003). Les 
EPCs et les cellules souches hématopoïétiques ont une origine commune. Les EPCs humaines 
expriment l’antigène CD133 (présent sur les cellules souches), le VEGFR-2 (vascular 
endothelial growth factor receptor 2, aussi appelé KDR/Flk-1) ainsi que le CD34. L’injection 
d’EPCs humaines directement dans le muscle permet l’amélioration de la circulation sanguine 
des membres ischémiques de souris (Kalka et al., 2000). De plus, il a été montré que les EPCs 
sont capables de se trans-différencier en cardiomyocytes (Condorelli et al., 2001), bien que cela 
reste un fait encore controversé. Cependant, la greffe de cellules par injection est inefficace, en 
effet plus de 90% des cellules sont soit perdues soit ne parviennent pas à s’intégrer (Zammaretti 
and Jaconi, 2004). C’est pour cette raison que la stratégie thérapeutique actuelle s’oriente vers la 
bio-ingénierie. Il s’agit par exemple d’utiliser des biomatrices capables d’offrir un support plus 
proche des conditions in vivo des cellules et par la même, favorisant leur survie et leur 
intégration une fois greffées. Ainsi, l’ingénierie tissulaire apparaît comme une technique 
prometteuse pour la distribution de facteurs angiogéniques et/ou de cellules capables de 
régénérer un tissu endommagé.  
Les biomatrices à base de fibrine apparaissent d’ores et déjà comme prometteuses pour ce 
type d’applications. En effet, la fibrine, qui est un acteur central de la coagulation sanguine, 
forme un échafaudage réticulé pour stabiliser le caillot. Toutefois, la cinétique de relâchement du 
VEGF simplement mélangée à de la fibrine est très rapide, ainsi, de 70 à 100% du facteur est 
déjà relâché après 24 heures (Ehrbar et al., 2004 ; Shireman et al., 1999). Pour éviter cela, une 
stratégie consiste à coupler le VEGF de manière covalente à la fibrine. Ainsi, le relâchement du 
VEGF est alore déterminé par la dégradation graduelle de la matrice de fibrine. La plasmine ou 
les métalloprotéinases produites par les cellules qui envahissent la matrice sont responsables de 
cette dégradation. De plus, le VEGF conjugué à la fibrine, une fois relâché, reste actif et agit 
comme un mitogène pour les cellules endothéliales (Zisch et al., 2001), et est également capable 
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de favoriser la formation de nouvelles branches artériennes et veineuses dans la membrane 
chorioallantoïque de l’embryon de poulet (Ehrbar et al., 2004).  
Un des premiers matériaux utilisé pour l’ingénierie tissulaire du cœur consistait en polymères 
hydrolysables d’acide polyactique, d’acide polyglycolique et leur co-polymère, l’acide 
polyactique-co-glycolique (Zund et al., 1997). Par la suite, les chercheurs ont montré que les 
propriétés mécaniques de la matrice devaient, idéalement, être adaptées aux propriétés élastiques 
du tissu cardiaque. A présent, plusieurs groupes expérimentent l’utilisation de polymères 
naturels, tel que le collagène, avec des résultats prometteurs (Akhyari et al., 2002 ; Zimmermann 
et al., 2002). 
 
Méthodes et Résultats 
 
Le but de ce travail de thèse était d’investiguer si des stratégies d’ingénierie tissulaire 
pourraient avoir un effet régénérant sur le coeur après infarctus du myocarde. Afin de stimuler la 
néoangiogenèse, nous avons utilisé des gels de fibrine pour délivrer directement sur le myocarde 
du VEGF ou des EPCs sélectionnées par l’expression de CD133. Nous avons comparé l’effet des 
implantations dans un modèle d’infarctus du myocarde chez le rat.  
Nous avons étudié spécifiquement les effets angiogéniques du VEGF attaché de manière 
covalente aux gels de fibrine dans des coeurs de rats normaux ou immédiatement après un 
infarctus du myocarde. Quatre semaines après l’implantation des gels, les résultats montrent que 
le VEGF peut promouvoir l’angiogenèse. En effet, il induit dans les coeurs infarcis et les coeurs 
normaux une formation de capillaires, mais pas de gros vaisseaux. L’effet induit est plus 
prononcé dans les régions ischémiques des coeurs infarcis que dans le myocarde normal. Le 
relâchement lent et continu du VEGF n’induit pas la formation d’hémangiomes. La fonction 
cardiaque des rats ayant subi un infarctus et reçu un gel contenant du VEGF semble être 
améliorée, bien que la différence avec les rats ayant reçu un gel sans VEGF ne soit pas 
statistiquement significative. En conclusion, le VEGF attaché de manière covalente aux gels de 
fibrine permet la formation de nouveaux capillaires, suggérant que ces matrices sont un vecteur 
efficace pour délivrer dans le coeur des facteurs angiogéniques.  
Concernant l’implantation de gels de fibrine contenant des EPCs, celle-ci a été faite soit dans 
des cœurs de rats normaux, soit dans des cœurs infarcis (directement après ligature ou une 
semaine après). Trois ou huit semaines après l’implantation des gels, nous n’avons pas pu 
retrouver les EPCs et aucun effet angiogénique n’a été détecté. La fonction cardiaque des rats 
transplantés n’a pas été améliorée. Bien que les résultats ne soient pas concluants à ce stade, 
nous allons modifier et améliorer nos stratégies d’implantation des cellules dans des matrices de 
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fibrines. Nous sommes confiants que l’implantation de cellules par cette méthode amènera des 
bénéfices et sera efficace dans le futur. 
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B. SUMMARY 
 
Despite advances in medical therapy and coronary revascularization strategies, ischemic 
heart disease remains the leading cause of congestive heart failure and cardiovascular mortality 
in industrialized countries. Restoration of a normal perfusion in the ischemic tissue is essential in 
the treatment of cardiac ischemia. Tissue engineering has also emerged as an attractive strategy 
for delivering angiogenic factors and/or cells to generate damaged tissue. Therapeutic 
angiogenesis by delivery of angiogenic factors like vascular endothelial growth factor (VEGF) 
and cell therapy by transplanting endothelial progenitor cells (EPCs) have shown a promising 
future for the treatment of myocardial infarction (MI).  
The aim of this thesis has been to investigate the relevance of tissue engineering strategies 
for the regeneration of the heart following MI. We have assessed the use of fibrin-based 
hydrogels to provide either VEGF or CD133-selected putative EPCs to the heart in order to 
stimulate neoangiogenesis. Specifically, we investigated 2 major questions: 
A. Angiogenic effects of VEGF121 covalently bound to fibrin gel in non-infarcted and 
infarcted rat hearts, after 4 weeks of implantation. In particular we tested: 
(1) whether VEGF121 covalently bound to fibrin gel could promote angiogenesis in the 
non-infarcted and infarcted rat hearts; 
(2) if this cell-demanded release of VEGF121 from fibrin gel could induce proper 
angiogenesis, without leading to hemangioma formation; 
(3) how far the angiogenic effect of VEGF121 (if any) can reach; 
(4) which kind of vessel VEGF can promote; 
(5) whether the angiogenic effect of VEGF121 (if any) can improve the heart function;   
(6) whether the fibrin gel per se has some angiogenic influences to the rat hearts. 
B. Possible vasculogenic or angiogenic effects of EPCs incorporated onto fibrin gels in the 
non-infarcted or infarcted rat hearts after 3 or 8 weeks of transplantation: 
(1) whether EPCs delivered by fibrin could proliferate in the non-infarcted and infarcted rat 
hearts, incorporate to the neovessels and thus promote neovascularization; 
(2) whether EPCs delivery to the heart can improve heart function. 
 The results show that:  
(1) VEGF covalently immobilized in the fibrin gel could promote angiogenesis by increasing 
capillary formation in the non-infarcted and infarcted rat hearts, an effect more pronounced in 
the ischemic area of infarcted rat hearts. Our controlled sustained low dose release of VEGF 
prevented the formation of aberrant vessels. Infarcted rats with VEGF-gels have a trend to have 
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better cardiac function compared to the rats with empty gels. Thus, fibrin gel matrices constitute 
an efficient vehicle for delivering angiogenic factors to the heart. 
 (2) under our experiment conditions, transplanted EPCs did not elicit angiogenesis and we 
did not observe an improved cardiac function in the rats with EPCs by echocardiography. 
Although our EPC results were not positive at this point, we will modify and improve our 
strategy of cell delivery through fibrin matrices and we are confident that such a cell delivery 
system will prove beneficial and effective in the future. 
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C. INTRODUCTION 
 
1. Treatment of ischemic heart disease  
Despite advances in medical therapy and coronary revascularization strategies, ischemic 
heart disease remains the leading cause of congestive heart failure and cardiovascular mortality 
in industrialized countries. The limited ability of the heart to regenerate damaged tissue 
following myocardial infarction results in loss of cardiac function, ventricular remodeling, and 
progressive dysfunction leading to congestive heart failure (Abbate et al., 2002). Current 
therapies address this process by: (1) reducing the duration of ischemia by surgically or 
pharmacologically removing the vascular blockage; and (2) using drug therapy (Angiotensin-
converting Enzyme inhibitors and beta blockers) to mitigate ventricular remodeling (Fonarow, 
2000). While these approaches have a substantial impact in the management of heart attacks 
there remains a considerable amount of room for improvement. The ideal therapy would bring 
the advantages to: 1) minimize the loss of cardiomyocytes by reducing cell death, 2) promote 
return of stunned and hibernating myocardium (ischemia-induced dysfunctional/non-contracting 
but alive myocardium) to normal function, 3) stimulate revascularization of the ischemic region 
by enhancing angiogenesis, and 4) regenerate viable cardiomyocytes to replace those lost to the 
initial ischemia thereby preserving contractile function and reducing the opportunity for scarring. 
 
2. Therapeutic angiogenesis 
Rapid sustained return of normal perfusion to the ischemic tissue is essential in the treatment 
of cardiac ischemia. Strategies such as percutaneous coronary intervention (PCI) and coronary 
artery bypass surgery (CABG) improve long-term survival and provide relief from symptoms. 
However, bypass grafts suffer from progressive atherosclerotic occlusion, and the procedure is 
limited by a finite number of conduits available for subsequent revascularization. Percutaneous 
coronary interventions are subject to relatively high rates of restenosis at the current time, 
although these outcomes can be expected to improve in the near future with advancements in the 
field. Moreover, a significant number of individuals have an unfavorable occlusive pattern, 
diffuse coronary atherosclerosis, small distant vessels and comorbidities that may preclude the 
application of one or both of these treatments, or have incomplete revascularization with these 
standard procedures. A recent study found that approximately 12% of patients with symptomatic 
obstructive coronary artery disease with documented ischemia, who were referred for coronary 
angiograms, were not candidates for PCI or CABG (Mukherjee et al., 1999). In another study, in 
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patients with 2- and 3-vessel disease, complete revascularization of hemodynamically significant 
stenoses was successful in 23 and 9% of cases, respectively (Bourassa et al., 1992). As a result, 
many of these patients have residual symptoms of myocardial ischemia despite medical therapy. 
Furthermore, even in the context of conventional therapy, the rate of spontaneous 
neoangiogenesis is insufficient to keep pace with loss of stunned and hibernating myocardium by 
ischemia-induced apoptosis and the need for compensatory proliferation.  
Against this backdrop, the field of therapeutic angiogenesis has emerged as an attractive 
treatment strategy for patients with diffuse atherosclerotic disease who are otherwise not 
candidates for conventional revascularization procedures such as PCI or CABG. 
Therapeutic angiogenesis can be defined as the delivery of angiogenic cytokines, either by 
direct protein administration or by gene therapy, to cause neovascularization and promote the 
development of supplemental collateral blood vessels acting as endogenous bypass conduits 
around occluded native arteries (Syed et al., 2004). 
In the past 20 years, successful therapeutic angiogenesis has been demonstrated in various 
animal models of myocardial ischemia using a number of growth factors administered either 
directly or by gene transfer. Successful preclinical studies and promising early results in clinical 
trials have also created great excitement about the potential of therapeutic angiogenesis. 
However, data from the few larger randomized double-blinded trials that have been conducted so 
far did not yet conclusively demonstrate the efficacy of therapeutic angiogenesis for myocardial 
ischemia. Indeed, these studies are limited by flaws in the delivery strategies employed in the 
trials (Simons et al., 2002; Henry et al., 2001; Hendel et al., 2000).  
 
 
3. The role of VEGF in the therapeutic angiogenesis 
More than 20 compounds have been identified until now with angiogenic activity (Lei et al., 
2004), as reported in Table A. Of these compounds, fibroblast growth factor (FGF) and vascular 
endothelial growth factor (VEGF) have been studied most widely for their angiogenic activity 
both in animal and human studies. 
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VEGF is the major angiogenic factor involved in physiological as well as pathological 
angiogenesis (Ferrara, 2001). The neovascularization is mainly achieved by endothelial cell 
proliferation triggered through VEGF receptors, especially the VEGF receptor 2 (Fig. A). Since 
the two VEGF high-affinity transmembrane receptors VEGFR-1 (flt-1) and VEGFR-2 (flk-
1/KDR) are only localized to endothelial cells and their embryonic precursors (angioblasts), this 
accounts for the specificity of the VEGF response of endothelial cells alone (Ferrara and Davis-
Smyth, 1997). Aside from VEGF inducing the proliferation and migration of endothelial cells, it 
also inhibits apoptosis in endothelial cells by inducing expression of the antiapoptotic genes bcl-
2 and A1, then VEGF is also believed to play a role in vascular stabilization (Gerber et al., 1998).  
The importance of VEGF in angiogenesis has been highlighted in studies of VEGF knockout 
mice, where inactivation of even a single VEGF allele (i.e. heterozygous genotype) resulted in 
abnormal vascular development and in embryonic lethality by early gestation (Carmeliet et al., 
1996; Ferrara et al., 1996). Equally importantly, models of experimental vascular occlusion and 
evidence of upregulated endogenous VEGF expression in the setting of tissue ischemia, as well 
as the potency of administering exogenous VEGF, highlight the importance of VEGF in 
postnatal vascular development and stabilization. 
VEGF was first discovered as a tumor angiogenesis factor by Folkman in 1971 (Folkman et 
al., 1971), and then in 1983, Senger et al. (Senger et al., 1983) named it as vascular permeability 
factor. It was only in 1989 that VEGF was isolated and sequenced as a 45-kD protein, verified as 
Table A. Pro-angiogenic factors
__________________________________________________________________ 
Angiopoietins (Ang) Ang-I,  Ang-II 
Angiogenins Angiogenin-1, Angiogenin-2 
Ephrins 
E-selectin 
Fibroblast growth factors (FGFs)        Acidic FGF, Basic FGF, and FGF3–9 
Heparin 
Hepatocyte growth factor 
Insulin-like growth factor 
Platelet derived growth factor 
Prostaglandins (PG)  
Thrombospondin 
Transforming growth factor (TGF-β) 
Tumor necrosis factor (TNF-α) 
Vascular endothelial growth factors (VEGF)      VEGFA 121, 145, 165, 189, 206 
 VEGFB 
 VEGFC 
 VEGFD 
 VEGFE 
 Placental growth factor __________________________________________________________________ 
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a mitogen for cultured endothelial cells and got its name “ vascular endothelial growth factor, 
VEGF” (Ferrara and Henzel, 1989; Plouet et al., 1989).  
 
 
Figure A. VEGF and its receptors on endothelial cells. VEGFA binds both VEGFR-1 and VEGFR-2. In 
contrast, PLGF and VEGFB interact only with VEGFR-1. The orf-virus-derived VEGF-E is a selective 
VEGFR-2 agonist. VEGFC and VEGFD bind VEGFR-2 and VEGFR-3. There is much evidence that 
VEGFR-2 is the major mediator of EC mitogenesis and survival, as well as angiogenesis and 
microvascular permeability. In contrast, VEGFR-1 does not mediate an effective mitogenic signal in EC 
and it may, especially during early embryonic development, perform an inhibitory role by sequestering 
VEGF and preventing its interaction with VEGFR-2. Such a "decoy" role could be also performed by the 
alternatively spliced soluble VEGFR-1 (figure from (Ferrara et al., 2003). 
 
The discovery of VEGF has been one of the theoretical foundations of the field of therapeutic 
angiogenesis. Afterwards, many studies either in animals or in human beings have focused on 
the assessment of VEGF angiogenic efficacy and safety. However, many important questions 
remain to be addressed, like what will be the optimal route of administration and the optimal 
method of delivery. Indeed, given that VEGF has the potential to have side effects like 
hypotension through a nitric oxide-mediated pathway (Horowitz et al., 1997), vascular 
permeability (Thurston et al., 2000; Senger et al., 1983), exacerbation of proliferative 
retinopathy (Aiello, 1997) or induction of tumor growth, a high drug target level and low 
systemic exposure should be the ultimate goal.  
Until now, several routes of administration of VEGF have been practiced. Among them, 
intravenous (Sato et al., 2001) and repetitive intra-atrial (Lazarous et al., 1996) injection were 
proved not effective. Even though intracoronary injection may be more effective, a considerable 
proportion of an angiogenic factor will enter the systemic circulation and thereby expose non-
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target tissues to its biologic effects (Laham et al., 1999). However, intramyocardial delivery of 
growth factors is preferable since it includes the possibility of targeting the desired areas of the 
heart, and has a higher efficiency of delivery and prolonged tissue retention (Laham et al., 1999). 
Intrapericardial administration is also appealing as a local delivery (Laham et al., 2000). 
Since the development of new blood vessels in ischemic tissues needs weeks and before neo-
vessel maturation, vessels are dependent on the continued presence of VEGF to prevent vessel 
regression and endothelial cell apoptosis (Richardson et al., 2001).  The duration of exposure of 
the vessels to VEGF is thus critical for a therapeutically relevant effect. Lazarous et al. 
demonstrated that 28 days of VEGF administration into the left atrium improved collateral flow, 
while 7 days of administration did not (Lazarous et al., 1996).  
Due to its short biological half-life, the VEGF protein, once injected intramyocardially, 
would be unlikely to persist in the tissue long enough to exert an important biologic effect. 
Although multiple injections might well improve collateral flow (Lazarous et al., 1996), such a 
strategy has practical limitations. Therefore, administration of genes encoding VEGF was 
explored as an approach to provide sustained VEGF. However, although prolonged presence of 
growth factors may be beneficial, there is no conclusive evidence to support this hypothesis. In 
fact, preliminary evidence suggests that prolonged but not controlled local production of VEGF 
may cause unwanted hemangioma or other vessel malformations (Lee et al., 2000; Schwarz et al., 
2000). Moreover, the theoretical advantage of gene therapy approaches with respect to longer-
term angiogenic factor exposure depends on effective local expression, which is usually not 
completely achieved because of high variability in the level and duration of gene expression. 
Various gene therapy vectors differ in their efficacy of cell transduction, the type of cells that get 
transduced, and duration and extent of transgene expression. Plasmid DNA and early generation 
adenoviral vectors mediate rather short-term (days to weeks) duration expression, while other 
viral vectors (retroviral, lentiviral) can result in a very long (months) duration of expression. The 
limited duration of transgene expression (～ 1-2 weeks) achieved in the heart with first 
generation adenovirus vectors makes them in some manner ideal for angiogenic gene delivery. 
However, this limited duration of expression is at least partially attributed to an immune 
response against adenoviral proteins and may be very short indeed in patients with pre-existing 
neutralizing antibodies (Post et al., 2001). The other drawback of the gene therapy approach is 
inconsistent level of expression achieved with the same dose in different patients. Therefore, 
given that VEGF protein therapy has the advantage of the precise knowledge of the delivered 
dose and the relatively well understood safety profile; it should be preferable to gene therapy if 
its limitation (the limited tissue half-life of VEGF) could be conquered. Actually, efforts have 
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been made in this domain. For instance, some approaches have been taken to prolong the serum 
half-life of angiogenic factor by amino acid mutation (Ortega et al., 1991); extended tissue 
exposure to the growth factor can be accomplished by a variety of slow release formulations (e.g. 
heparin-alginate beads) (Edelman et al., 1991). 
 
4. Endothelial progenitor cells (EPCs) and post-natal vasculogenesis  
The endothelial progenitor cells (EPCs) were first identified and isolated from adult 
peripheral blood (PB) by Asahara et al. in 1997(Asahara et al., 1997).  Over the past 8 years, this 
discovery and accumulated evidence to prove that EPCs have the potential to differentiate into 
endothelial cells ex vivo as well as in vivo have opened up a new field of cardiovascular research 
(Rafii and Lyden, 2003).  
EPCs are considered to share common stem/progenitor cells with hematopoietic stem cells 
(HSC) (Fig. B, C) and have been shown to derive from bone marrow (BM) and to incorporate 
into foci of physiological or pathological neovascularization. The finding that EPCs home to 
sites of neovascularization and differentiate into endothelial cells (ECs) in situ is consistent with 
‘vasculogenesis’, a critical paradigm well described for embryonic neovascularization, recently 
proposed in adults in which a reservoir of stem/progenitor cells contributes to post-natal vascular 
organogenesis. 
 
Figure B. Postnatal developmental differentiation of stem and progenitor cells. SC, stem cell  (figure 
from (Asahara and Kawamoto, 2004). 
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Figure C. Origin and differentiation of endothelial progenitor cells. The scheme depicts the potential 
origin and differentiation of EPCs from hematopoietic stem cells (figure from (Urbich and Dimmeler, 
2004). 
 
4.1 Post-natal neovascularization 
Through the discovery of EPCs in PB, our understanding of post-natal neovascularization has 
been expanded from angiogenesis to angio/vasculogenesis. As previously described (Folkman 
and Shing, 1992), post-natal neovascularization was originally recognized to be constituted by 
the mechanism of ‘angiogenesis’, which is neovessel formation, operated by in situ proliferation 
and migration of preexisting endothelial cells. However, the isolation of EPCs resulted in the 
addition of the new mechanism, ‘vasculogenesis’, which is de novo vessel formation, in situ 
incorporation, differentiation, migration, and/or proliferation of BM-derived EPCs (Asahara et 
al., 1999), as illustrated in Fig. D (Masuda and Asahara, 2003). 
More recently, tissue specific stem/progenitor cells with the potency of differentiation into 
myocytes or ECs were isolated in skeletal muscle tissue of murine hindlimb, although the origin 
remains to be clarified (Tamaki et al., 2002). This finding suggests that the origin of EPCs may 
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not be limited to BM, e.g. tissue specific stem/progenitor cells possibly provide ‘in situ EPC’ as 
other sources of EPCs than BM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure D. Post-natal neovascularization during physiological or pathological events is consistent with 
neovessel formation contributed by angiogenesis and vasculogenesis at the various rates between these 
two mechanisms. Angiogenesis and vasculogenesis are due to the activation of in situ ECs and BM-
derived or in situ EPCs, respectively. (Figure from (Masuda and Asahara, 2003). 
 
 
4.2 EPC phenotype(s) and characterization 
EPCs represent a small subpopulation (<0.05%) of the leukocyte fraction of BM-derived 
mononuclear hematopoietic cells in the adult (Assmus et al., 2002). Typically, mononuclear cells 
are isolated from bone marrow, peripheral blood, or cord blood by density gradient 
centrifugation and/or separation by magnetic beads or flow cytometry with antibodies against 
surface antigens such as CD34. The separation of presumptive EPCs from hematopoietic 
progenitors is complicated by the fact that EPCs and hematopoietic progenitors descend from a 
common ancestral precursor - the putative hemangioblast - and share multiple cell surface 
antigens, including CD34. 
‘Classical’ EPC cultures are short-term and originate from whole blood or CD34(+)-purified 
blood mononuclear cells by plating on fibronectin/gelatin-coated surfaces. Part of the cells 
adhere and differentiate towards an endothelial cell fate under selective growth conditions such 
as endothelial cell growth medium, VEGF or basic fibroblast growth factor (bFGF) 
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andepidermal growth factor (EGF). Typically, adherent cells are classified to be EPCs after 3-7 
days based on their cell morphology and are harvested for study. 
Human EPCs are defined by the expression of multiple cell surface antigens including human 
stem cell antigen CD133 (formerly known as AC133), VEGFR-2 (vascular endothelial growth 
factor receptor 2, also known as KDR and Flk-1), CD34, CD105 (endoglin), platelet endothelial 
adhesion molecule (PECAM or CD31), VE-cadherin, c-kit, von Willebrand factor, CD146, and 
CXCR4 (the receptor for stromal cell-derived factor 1). Several of these expression markers, as 
well as in vitro EPC functions such as the uptake of Ulex europeas lectin, or capillary tube 
formation, are shared by mature ECs, HSCs, and myelomonocytic cells (Schmeisser et al., 2003). 
By current knowledge, the surface antigen CD133, a glycoprotein of yet unknown function, 
provides the most reliable means to define and track human angioblast-like EPCs and distinguish 
them from mature endothelial or monocytic cells. CD133 expression ceases during EPC 
differentiation (Peichev et al., 2000), is lost in mature endothelial cells, and is absent in 
monocytic cells.  
Based on classical EPC isolates derived from short-term culture, an array of EPC 
characteristics has been evaluated in vitro and in vivo. Central to the interpretation of these 
studies has been the assumption that cultivated EPCs possess angioblast-like properties, i.e. 
being migratory, highly proliferative, and capable of differentiating into mature endothelial cells 
in situ. This assumption is challenged by recent findings that EPC populations derived by such 
classical fractionation methods are heterogeneous in nature, and that only a small cellular subset 
possess angioblast-like characteristics (Gulati et al., 2003). A second and much bigger subset of 
primary adherent ‘EPCs’ are transdifferentiated CD14(+)-monocytic cells that are capable to 
assume expression and phenotypic features of ECs in angiogenic culture conditions (Rehman et 
al., 2003). 
In long term culture (>2 weeks), angioblast-like EPCs form endothelial colonies with 
extraordinary proliferative capacity (late outgrowth endothelial cells or OECs); in contrast, 
monocytic EPCs proliferate slowly and die within 2-3 weeks (Gulati et al., 2003). Regardless of 
their lineage, the therapeutic potential of both angioblast-like CD14(-) as well as monocytic 
CD14(+) cells has been validated in vivo: both subsets were shown to incorporate into vascular 
structure of mice after hindlimb ischemia and to significantly improve neovascularization 
(Urbich et al., 2003). These cell subsets may contribute to new vessel growth by different 
mechanisms; angioblasts-like EPCs may contribute by serving as a cellular substrate (i.e. 
physically integrating into new vessels), while monocytic ‘EPCs’ may enhance the angiogenic 
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process in general, via release of inflammatory mediators that stimulate granulation tissue 
formation, including angiogenic growth factors like VEGF (Zammaretti and Zisch, 2005).   
 
4.3 Physiological functions of EPCs 
Adult, healthy vasculature is thought to be relatively stable and to exhibit a very low EC 
turnover rate, i.e. τ1/2 3 years (Schwartz and Benditt, 1976). Under steady-state conditions, 
circulating EPCs represent only ~ 0.01% of cells in the circulation. In the healthy adult life, 
EPCs may participate in ongoing endothelial repair. More intriguingly, bone marrow EPCs may 
constitute a cellular reservoir, which can be called upon with acute demand in conditions of 
major vascular insult. Bone marrow EPC levels respond rapidly to both endogenous as well as 
exogenous signals. Rapid but transient mobilization of CD133(+)VEGFR-2(+)EPCs into the 
circulation has been measured in human patients experiencing acute vascular trauma secondary 
to burn injury or coronary artery bypass grafting (Gill et al., 2001). Within 6-12 h after injury, 
the percentage of circulating EPCs increased almost 50-fold before returning to basal levels 
within 48-72 h. Plasma VEGF levels were found to be similarly upregulated, suggesting VEGF 
as a key regulatory signal of EPC mobilization and differentiation. Aside from trauma, regional 
ischemia has been recognized as a potent endogenous stimulator of EPC mobilization. Direct 
evidence that EPCs were specifically mobilized from the BM in response to ischemia was 
obtained in murine transplantation models using genetically marked donor marrow (Takahashi et 
al., 1999). Presumably, this effect is mediated by upregulated VEGF levels during ischemia. 
Biodistribution studies of intravenously injected radiolabeled EPCs have shown that myocardial 
infarction profoundly enhanced homing of EPCs to the infarct zone (Aicher et al., 2003).  
 
4.4 EPCs for therapeutic revascularization 
Human EPCs have been isolated from BM aspirates, peripheral blood, and cord blood. EPC 
isolates, re-introduced by injection or infusion into heart or limb, have been shown to maintain 
their ability to participate in endothelial/vessel growth at sites of ischemia or vessel injury. 
Specifically, locally grafted EPCs showed positive effects for (1) improving regional blood in 
ischemic heart disease and peripheral arterial disease; (2) inhibiting neointimal hyperplasia by 
growing new endothelium in denuded arteries after balloon angioplasty; and (3) generating 
endothelialized, non-thrombogenic bioprosthetic vessel graft surfaces(Rafii and Lyden, 2003).  
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5. Strategies of Tissue engineering: biomatrices for angiogenic 
factor delivery and cell transplantation 
 
5.1 Biopolymeric delivery matrices for angiogenic growth factors  
As discussed above (section 3), preclinical and clinical exploration of therapeutic 
angiogenesis has indicated a need for continuous local delivery of low dose of angiogenic 
activities to produce functional vasculature at the target sites. In this respect, incorporation of 
growth factors into depot vehicles can provide a means to increase the persistence of growth 
factor at the disease site, and a variety of natural or synthetic polymers have been actively 
investigated and employed as carrier devices for angiogenic growth factors. 
As the extracellular matrix (ECM) plays a highly functionalized role in modulating the 
stability, activity, release and spatial localization of growth factors involved in a morphogenetic 
response (Zisch et al., 2003), the desire for functional mimetics of natural ECM that protect 
growth factor activities and achieve more timely and spatially controlled delivery has spurred the 
development of technologies for protein or cell packaging inside biomaterial-based implant 
devices. Natural and synthetic molecules have been employed as bulking agents to embed 
angiogenic proteins. Experimentally and clinically applied bulk materials belong to mainly two 
categories: dense solids and hydrogels.  
Dense solids can be processed into porous scaffolds that provide mechanical support for cells 
or microspheres for injection within tissue sites. Hydrogels are defined as three-dimensional 
polymer networks swollen by water, which is the major component of the gel system. These low-
density materials can be classified based on the mechanisms by which the cross-links within the 
networks are produced: physical gels, chemical gels and intermediated-type gels. The cross-link 
density in these materials can be such that the permeability of proteins through the order 100-nm 
pores is relatively rapid. As such, affinity sites can be incorporated within the material to provide 
for association and dissociation with a diffusible growth factor (Zisch et al., 2003). 
Natural macromolecules that produce physical gels include several polysaccharides (alginate, 
chitosan, hyaluronan, agarose) and proteins (fibrin, collagen, gelatin), and many of them can be 
converted to chemical gels under some enzymatic cross-linking action, e.g. for collagen and 
fibrin with transglutaminases. Synthetic polymers include some commercial block copolymers 
such as poly(ethylene oxide-b-propylene oxide-b-ethylene oxide) (PEO-PPO-PEO) and triblock 
copolymers of poly(ethylene glycol) and poly(lactic or glycolic acid) (PEG-PLGA-PEG) (Jeong 
et al., 2000). In these latter two types of injectible hydrogels, solidification from the liquid 
precursor occurs by shift from low to body temperature. 
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Among the natural matrices for angiogenic growth factor delivery, fibrin gel is a promising 
candidate. Fibrin is the major constituent of blood clots, which form in immediate response to 
vessel injury and tissue damage and thus serve as a natural provisional material platform for new 
cell ingrowth to be replaced by viable tissue during wound regeneration. Fibrin is resorbed by 
degradation via cellularly produced fibrinolytic enzymes. Commercial fibrin precursor 
preparations, termed ‘fibrin glue’, are a mixture of concentrated fibrinogen and thrombin which 
is usually derived by cryoprecipitation of human plasma and are widely used as tissue sealants in 
surgery. Because fibrin lyses slowly, it can serve as provisional reservoir to deliver angiogenic 
proteins or cells (Zisch et al., 2003).  
However, the release kinetics of simple admixture of VEGF and fibrin glue is only indicative 
of an uncontrolled burst release, showing release of 70-100% of the growth factor initially added 
to the fibrin glue after 24 hours (Ehrbar et al., 2004; Shireman et al., 1999). To prevent the burst 
release of VEGF incorporated with fibrin, a new attractive strategy for VEGF delivery has been 
designed. This novel methodology allows the covalent incorporation of VEGF fused to 8 amino 
acid peptide of the plasmin inhibitor (α2−PI1-8) into fibrin by the transglutaminase activity of 
factor XIIIa during coagulation. The VEGF121 isoform of the VEGF-A family (α2−PI1-8-VEGF121) 
was chosen because unlike other isoforms such as VEGF165, VEGF121 is an acidic diffusible 
polypeptide unable to bind heparin. This approach can prevent rapid clearance of VEGF from 
fibrin by coupling its release to the gradual degradation of the fibrin matrix by plasmin or matrix 
metalloproteinases (MMPs) produced in the local milieu at the surface of cells that invade the 
matrix.  
The immobilized, fibrin-conjugated VEGF121 protein has been demonstrated to remain an 
active and very efficient mitogen for human endothelial cells (Zisch et al., 2001), and to be 
capable to increase the formation of new arterial and venous branches in the embryonic chicken 
chorioallantoic membrane (Ehrbar et al., 2004).  Permeability studies in mice validated that the 
new-formed vessels induced by α2−PI1-8-VEGF121 are not leaking (Ehrbar et al., 2004).  
 
5.2 Materials as scaffolds for cell transplantation (Tissue engineering) 
Tissue regeneration by injection of new cells has emerged in the last years as one of the most 
promising therapies for many diseases involving tissue or organ destruction. Most effort is 
centered on the use of stem cells from embryonic, fetal or adult origin for the regenreration of 
damaged tissues. However, the efficacy of cell engraftment by injection of a cell suspension is 
generally very low as more than 90% of the cells injected is lost and does not engraft 
(Zammaretti and Jaconi, 2004). Thus, much effort is now conveyed to the development of tissue-
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engineering strategies using biomatrices to generate three-dimentional cell constructs able to 
provide a physiological support to the cells, allowing to successfully engrafting new cells into 
the myocardium. 
One of the first materials used for tissue engineering of the heart was based on hydrolytically 
degradable biocompatible polymers composed of polyactic acid, polyglycolic acid (PGA) and 
their copolymer polylactic-co-glycolic acid (PLGA) (Zund et al., 1997). Subsequently, 
researchers realized that the mechanical properties of the material used had to be adapted to the 
elastic properties of the heart tissue. Therefore, most research is focusing on the use of hydrogels 
made of different synthetic and/or natural polymers. Table B (Zammaretti and Jaconi, 2004) 
gives an overview on different materials used in the past few years for the regeneration of the 
heart. It has to be pointed out that only a few materials were tested in humans, while many 
animal studies were carried out in rats and dogs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Table from (Zammaretti and Jaconi, 2004). 
 
Several groups are currently working with scaffold materials composed of natural polymers 
such as collagen (Zimmermann et al., 2004; Akhyari et al., 2002; Zimmermann et al., 2002), this 
latter being the major constituent of the cardiac ECM. Promising results in the development of 
collagen-based grafts or ‘patches’ containing beating cardiomyocytes were obtained in Canada 
(Akhyari et al., 2002) and Germany (Zimmermann et al., 2002). These studies comprised the 
application of cardiomyocyte-seeded collagen strings that were cyclically stretched, thus 
Table B. Materials used in the past three years for cardiac tissue engineering 
___________________________________________________________________________ 
Natural 
Gelatin scaffolds  
Acellular porcine scaffolds 
Porous alginate scaffolds 
Alginate–gelatin–PEGa scaffolds  
Collagen scaffolds 
Fibrin glue 
 
Synthetic 
PLA–PGA 
Poly-L-lactide-gelatin–PGA 
Electrically conducting membrane layers composed of PGA, gelatin, alginate and/or collagen 
Polyvinyl alcohol 
PGA-co-polyhydrobutyrates 
e-Caprolactone-co-L-lactide 
Polyurethanes  
TMC-co-e-caprolactone-co-D-L-lactide 
___________________________________________________________________________ 
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providing patches with improved morphology and contractile function. Zimmermann et al. 
demonstrated that these collagen patches could survive and beat for up to eight weeks after 
engraftment on the heart of immunosuppressed rats (Zimmermann et al., 2004). Similar 
approaches and results were obtained using alginate-based scaffolds by Cohen et al. in Israel 
(Dar et al., 2002; Leor et al., 2000). Alginate, a negatively charged polysaccharide from seaweed 
which forms hydrogels in the presence of calcium, offers the advantage of detecting ECM 
formation by cardiac cells to follow not only the proliferation and migration of the cells, but also 
the kinetics of ECM formation. After implantation into the infarcted rat myocardium, the 
alginate-biografts were shown to stimulate intense neovascularization and to attenuate left 
ventricular dilatation and failure, compared with control rat hearts (Leor et al., 2000).  
Composites of natural and synthetic polymers were also developed; for example, sponges 
based on -caprolactone-co-L-lactide reinforced with knitted poly-L-lactide fabric (PCLA), 
gelatin or PGA. Using rat aortic smooth muscle cells, an increased colonization of the right 
ventricular outflow tract was obtained using gelatin or PCLA, but not with PGA-reinforced 
grafts (Ozawa et al., 2002).  
Another interesting synthetic material is based on 1,3-trimethylene carbonate and D,L-lactide 
copolymers (Pego et al., 2003a; Pego et al., 2003b), which have the ability to be readsorbed over 
a ten month period and to sustain the cyclic loading of the heart muscle under physiological 
conditions. However, as yet no animal studies have been carried out with this amorphous 
material.  
The most fascinating approach to the regeneration of heart has been proposed by Shimizu 
and co-workers (Shimizu et al., 2003), who used materials to create electrically communicating 
three-dimensional cardiac tissue layers (Fig. E, panel c). In this case, cells were adhered on 
tissue-culture plates previously coated with poly(N-isopropylacrylamide) (PIPAAm), a 
temperature-sensitive polymer. At 37°C PIPAAm is hydrophobic, enabling cell adhesion and 
access to the binding sites offered on this modified surface; at a lower temperature such as 32°C, 
the surface becomes hydrophilic and inappropriate for cell adhesion due to the rapid hydration 
and swelling of PIPAAm. Using poly(vinylidene difluoride) (PVDF) membranes, which are 
hydrophobic, the detaching cell layers can be collected and handled, providing up to four 
conducting layers of synchronously beating cardiomyocytes. When these patches were implanted 
on rats with induced myocardial infarction, an improved myocardial contractility was observed, 
concomitant with the appearance of a vascular network within a few days after implantation 
(Shimizu et al., 2003). Figure E summarizes three of the major approaches to cardiac 
engineering described above, based on the use of collagen, hydrogel or multiple layers.  
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Figure E. Scheme of the present major strategies of cardiac tissue engineering using (a) collagen strings, 
(b) biodegradable gels or (c) cardiac cell sheets. The incorporation of growth factors and/or cytokines 
(triangles) may have a crucial role to support cell differentiation, engraftment and survival, both within 
the scaffolds and in vivo, thus improving the overall cardiac function. (Figure from (Zammaretti and 
Jaconi, 2004). 
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D.  AIM OF THE STUDY 
 
The aim of this thesis has been to investigate the relevance of tissue engineering strategies 
for the regeneration of the heart following myocardial infarction. We have assessed the use of 
fibrin-based hydrogels to provide either angiogenic factors or progenitor cells to the heart in 
order to stimulate neoangiogenesis. 
 
1. Delivery of VEGF covalently bound to fibrin gels  
First of all, the present study was designed to investigate the following questions: 
(1) whether VEGF121 covalently bound to fibrin gel could promote angiogenesis in the non-
infarcted and infarcted rat hearts; 
(2) if this cell-demanded release of VEGF121 from fibrin gel could induce proper 
angiogenesis, without leading to hemangioma formation; 
(3) how far the angiogenic effect of VEGF121 (if any) can reach; 
(4) which kind(s) of vessel(s) VEGF can promote; 
(5) whether the angiogenic effect of VEGF121 (if any) can improve the heart function;   
(6) whether the fibrin gel per se has some angiogenic influences to the rat hearts. 
 
2. Delivery of EPCs incorporated into fibrin gels 
 
The in vivo study of EPCs delivered by fibrin gel was designed to address the following 
questions: 
(1) whether EPCs delivered by fibrin could proliferate in the non-infarcted and infarcted rat 
hearts, incorporate to the neovessels and thus promote neovascularization;  
(2) whether EPCs delivery to the heart can improve heart function. 
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E. MATERIALS AND METHODS 
 
1. Preparation of fibrin gel matrices 
Fibrin gel matrices were prepared by mixing the following components at the final 
concentrations of 10mg/mL fibrinogen (Fluka AG), 2 U/mL factor XIII (Baxter AG, Vienna), 
and 2.5 mM CaCl2 (Zisch et al., 2001). Fibrin gelation is initiated by addition of 2 NIH units/mL 
of human thrombin (Sigma, St. Louis, MO). 100μL fibrin gel/well were put into 8-well chamber 
slides to construct the three dimensional matrices. Fibrin polymerization was allowed to proceed 
for 30 min at 37 °C in a humid atmosphere. The materials were kindly provided by Dr. Prisca 
Zammaretti, Dr. Martin Ehrbar and Prof. Andreas Zisch, our collaborators at the Institute for 
Biomedical Engineering, Swiss Federal Institute and University of Zurich (EPFZ) and EPFL. 
 
2.  Preparation of VEGF121covalently bound in fibrin gel matrices 
 
2.1 Preparation of recombinant α2−PI1-8-VEGF121  
The preparation of recombinant α2−PI1-8-VEGF121, containing the factor XIIIa substrate 
sequence NQEQVSPL at the amino terminus of mature human VEGF121, has been described by 
Zisch et al. (Zisch et al., 2001). Briefly, a BamHI to EcoRI mutant DNA fragment corresponding 
to α2-PI1–8-VEGF121, which contains a factor XIII substrate sequence NQEQVSPL at the 
aminoterminus of mature VEGF121, was generated by PCR-based mutagenesis using the full 
length cDNA of human VEGF121 as a template. The PCR fragment was inserted as 
BamHI/EcoRI digest into pGEX-4T3 (Pharmacia) and cloned in the E. coli strain XLI Blue. 
Clones containing the correct VEGF cDNA insert were identified by sequencing. For protein 
expression as His-tagged protein, the BamHI/EcoRI insert was subcloned into a modified pRSET 
T7 expression plasmid that contains the thrombin cleavage site GLVPRG between the histidine-
tag sequence and the BamHI site. The resulting plasmid pRSET-α2-PI1–8-VEGF121 contained a 
VEGF121-construct with following features: an aminoterminal His-tag linked to the thrombin 
cleavage site linked to α2-PI1–8-VEGF121.  
After His-tag removal by thrombin cleavage, a mutant α2-PI1–8-VEGF121 with an 
aminoterminal extra domain GSNQEQVSPL was obtained. For protein expression and 
purification, E. coli expression hosts BL21(DE3)pLysS or AD494 (DE3)pLysS (Novagen) were 
transformed with the pRSET-α2-PI1–8-VEGF121 plasmid. The recombinant VEGF protein was 
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isolated as histidine-tagged fusion protein from inclusion bodies and purified by His-Bind resin 
chromatography using the His-Bind kit (Novagen). 
 
2.2 Fibrin gel matrices formulated with α2−PI1-8-VEGF121  
Fibrin gel matrices were prepared by mixing the following components at the final 
concentrations of 10mg/mL fibrinogen (Fluka AG), 2 U/mL factor XIII (Baxter AG, Vienna), 
and 2.5 mmol/L CaCl2 (Zisch et al., 2001). α2−PI1-8-VEGF121 were mixed within the fibrinogen 
solution at a concentration of 150 μg/mL before initiation of fibrin gelation by addition of 
thrombin. Fibrin polymerization was allowed to proceed for 30 min at 37°C in a humid 
atmosphere. Fig. F illustrates the incorporation scheme of  α2−PI1-8-VEGF121 to fibrin gel (Zisch 
et al., 2001). Fibrin gel matrices formulated with of α2−PI1-8-VEGF121 were kindly provided by 
Dr. M. Ehrbar and Prof. AH. Zisch, our collaborators at the Institute for Biomedical Engineering, 
Swiss Federal Institute and University of Zurich (EPFZ) and EPFL. 
 
 
 
 
 
Figure F. Covalent conjugation of VEGF121 as 
bidomain peptide into fibrin. α2−PI1-8 represents 
an 8-amino-acid sequence derived from plasmin 
inhibitor and serves as substrate sequence for 
factor XIIIa-mediated crosslinking into fibrin. 
By this coupling scheme, VEGF121 is liberated 
by cleavage from the fibrin gel matrix only as 
cells locally remodel the fibrin via cell-
associated enzymatic activity, e.g. with MMPs 
or plasmin. (Figure from (Zisch et al., 2001). 
 
 
3. Preparation of EPCs seeded atop fibrin gel matrices 
 
3.1 Isolation of EPCs from human umbilical cord blood 
Umbilical cord blood (UCB) cell collection was approved by the ethics committee of the 
University Hospital Zurich. Typically, 50 ml of UCB could be collected from fresh placentas 
with umbilical cord into tubes containing citrate as anticoagulant. The UCB was diluted with two 
volumes of Ca2+- and Mg2+-free Dulbecco PBS (D-PBS). The mononuclear cells were isolated 
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by density gradient centrifugation with Biocoll (Oxid, Basel, Switzerland) and then washed three 
times in D-PBS. Positive selection of CD133-expressing putative EPCS was performed by a 
magnetic bead separation method (MACS; Miltenji Biotec, Gladbach, Germany), using the 
manufacturer's protocol. 
 
3.2 Preparation of fibrin gel matrices seeded with EPCs for transplantation 
The fibrin gels were formulated with 2 mg/mL fibrinogen, 0.5 U/mL factor XIII and 2 NIH 
units/mL human thrombin. 106 MACS-selected CD133+ cells in 350 μL endothelial cell growth 
medium (Clontech) were seeded atop the fibrin gel substrates. The culture medium was changed 
after 24 h. A second change of medium after another 48 h was found critical for cell survival. 
Subsequent changes of EC culture medium were performed after 48 or 72 h. In each change, 300 
μL culture supernatant was removed and replaced with an equal volume of fresh endothelial cell 
growth medium. The culture was performed at 37ºC under 5% CO2, and after 7 days of culture, 
the cells were ready for in vivo transplantation with the fibrin gel matrices (Figure G). Fibrin gel 
matrices seeded with EPCs were kindly provided by Dr. P. Zammaretti, our collaborator at the 
Institute for Biomedical Engineering, Swiss Federal Institute and University of Zurich (EPFZ) 
and EPFL. 
 
 
  
 
 
 
 
Figure G. In vitro engineered 3D-fibrin gels seeded with EPCs to form “cardiac patches”. 
 
4. Experimental animal protocol 
 
4.1 Experimental animal protocol for VEGF study 
All the animal experiments were performed under the authorization of the Cantonal 
veterinary office. A total of 14 male Sprague-Dawley (SD) rats (CHARLES RIVER 
Laboratories, France) were included in this experiment, 6 of them received left anterior 
descending artery (LAD) ligation to induce the left ventricular myocardial infarction (MI). 3 
   EPCs  
ba 
Cardiac patches  
implanted onto 
left ventricle  
7 days 
 31
non-infarcted and 3 infarcted rats were implanted with fibrin gels covalently conjugated with 
VEGF. As a control, 2 non-infarcted rats and 3 infarcted rats received empty fibrin gels; other 3 
normal rats with no treatment at all were use as control for the histology studies. In the infarcted 
rats, implantations were performed immediately after the ligation. All rats were kept for 4 weeks 
and before sacrifice, the heart function was evaluated by echocardiography (see section 8). Fig. 
H summarizes the experimental animal protocol.  
 
 
Figure H. Experimental protocol for VEGF Study. The rats receiving gel implantation were dividend into 
two groups: with or without MI. Evaluation of the left ventricular function was performed by 
echocardiography just before animal sacrifice. 
 
  
4.2 Experimental animal protocol for EPCs study  
Twenty seven male Sprague-Dawley (SD) rats (9 week-old, weight 300-350 g, CHARLES 
RIVER Laboratories, France) were included in this experiment. The animals were divided into 3 
main groups as illustrated in figure I: group 1: non-infarcted rats (n=9); group 2: rats engrafted 
immediately after MI (n=9); and group 3: rats engrafted 1 week after MI (n=9). 
For each group, the rats were sacrificed either 3 weeks or 8 weeks after implantation, 
illustrated also in Fig. I.  
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Figure I. Experimental protocol for EPCs Study.  The rats were divided into two groups: non-infarcted 
and infarcted. The animals implanted with EPC-seeded gels were immunosuppressed by CsA. Evaluation 
of the left ventricular function was performed by echocardiography before animal sacrifice.  
 
 
 
5. Rat model of myocardial infarction 
Male Sprague-Dawley (SD) rats weighing 300-350 grams were initially anesthetized with 4-
5% isoflurane in an induction chamber (Figure J). After shaving, the rat was intubated with a 14-
gauge catheter, tracheal ventilation was performed at 70 cycles/min with 2.5-3.0 mL tidal 
volume, room air supplemented with oxygen (Harvard Rodent Ventilator, Model 683, Harvard 
Apparatus Co, Inc). 1.5-2% isoflurane was maintained for continuous anesthesia. 
 
 
 
 
 
 
 
 
 
Figure J. Anesthesia chamber and ventilation setup.  
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A left intercostal thoracotomy was performed under aseptic technique. The forth-intercostal 
space was opened carefully to avoid accidentally cutting any vessels including the internal 
mammary artery. The forth and fifth ribs were separated with a small retractor (Harvard 
Apparatus, France) to expose the heart. The pericardium was incised, the left anterior descending 
coronary artery (LAD) was identified between the left atrial appendage and the right pulmonary 
outflow tract under surgical microscope. A 6-0 polypropylene suture was passed through the 
epicardium layer beneath the LAD 1 to 2 mm from its origin, tying the ligature permanently 
occluding the LAD (Ye et al., 1997). The occlusion was confirmed by the appearance of a 
hypokinetic whitish area.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure K. Panels a, b: ligation procedure. After a left intercostal thoracotomy was performed, the fourth 
intercostal space was opened and the ribs were separated with a small retractor in order to expose the 
heart. LAD was ligated by a 6-0 polypropylene suture. Panel c: Drawing illustrating that upon LAD 
ligation, the left ventricular anterior free wall becomes hypokinetic and pale due to the lack of blood 
supply. (Pictures provided by Dr. Qing He). 
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Infarcted 
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ligature 
a 
b 
c
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6. Transplantation procedure 
Fig. L schematically illustrates the two major cardiac conditions studied: a) non-infarcted 
versus b) infarcted hearts, engrafted with fibrin gels containing or not VEGF.  
 
 
 
 
 
 
 
 
 
 
Figure L. Fibrin gels, either empty or supplemented with VEGF were implanted onto (a) non-infarcted 
hearts, or (b) hearts undergoing MI. The gel was attached over the infarct and ischemic part and fixed 
with one or two sutures. For the non-infarcted rats, the gel was over similar area of the left anterior 
ventricular wall. 
 
After the positioning of the gel, muscle layers and skin were closed with 3-0 sutures. Post-
operative pain relief was achieved by the administration of buprenorphine (0.05-2.5 mg/kg s.c.). 
Upon rat wake up, extubation was performed and the rat was placed in a recovery cage with a 
supply of oxygen for 30 to 60 minutes. 
Fibrin gels seeded with or without EPCs were implanted on the non-infarcted, immediately 
after MI or 1 week after MI as described in Fig. I. Implantation procedures are illustrated in Fig. 
M. 
 
 
 
 
 
 
 
 
 
Figure M. Gels with or without EPCs were implanted on the non-infarcted or immediately, 1 week after 
MI depended on the protocol. The gel was attached over the infarct part, and fixed with one or two 
sutures, for the non-infarcted rats, the gel was over the similar area of the left anterior ventricular wall.  
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Transplantation procedures were the same as for the VEGF-loaded gels except that the gel had to 
be oriented with the side carrying the EPCs facing the epicardium.  
 For the rats received gels 1 week after MI, the chest was re-opened under anesthesia and the 
gel was positioned on the infarcted area identified on the basis of surface scar and wall motion 
abnormality. 
 
 
7. Immunosuppression treatment 
To prevent rejection of EPC-seeded gels, the rats were immunosuppressed by a cyclosporin A 
(CsA) delivered continuously via an osmotic minipump (length 5.1cm, diameter 1.4cm, weight 
5.1g, total displaced volume 6.5ml, reservoir volume 2ml, ALZET Corporation). Fig. N shows a 
rat implanted with minipump.  
 
 
 
 
 
                                                                         
 
 
 
 
 
 
Figure N. Rat with a subcutaneous implantation of an osmotic minipump filled with CsA. 
 
 
Alzet mini-osmotic pumps filled with CsA (Sandimmune, Novartis 50mg/1ml) were kept 
overnight at 37°C in PBS before implantation. The CsA release was adjusted at 2.5μl/hour and 
the pumps were designed for a 4 weeks release. For the rats that were kept for 8 weeks, the old 
pump was replaced by a new one after 4 weeks. The administrated dosage of CsA was calculated 
as 6-9 mg/Kg/day (Sullivan et al., 2000). After hair shaving and skin cleaning at the site for 
incision on the back, a hemostat was inserted into the incision to separate the subcutaneous tissue 
and create a prompt pocket for the pump. The filled pump was implanted subcutaneously and the 
wound was closed with suture. All procedures were performed under sterile circumstances. 
 
Osmotic minipump + CsA    
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8. Evaluation of the left ventricular function by echocardiography  
For the evaluation of left ventricular function, transthoracic echocardiography was performed 
on the rats before sacrifice. After the chest and neck were shaved, the rats were placed in dorsal 
decubitus position. Isoflurane (1-2%) was continuously supplied via a mask (Moises et al., 
2000).  
In vivo heart function was evaluated by echocardiography using a fully digitized Vingmed 
System Five (GE Vingmed Ultrasound, Horten, Norway) with a 10-MHz linear array transducer.  
The transducer was positioned on the left anterior side of the chest. At first, longitudinal images 
of the heart were obtained, including the left ventricle, the left atrium, the mitral valves and the 
aorta, followed by the cross-sectional images from the plane of the base to the left ventricular 
apical region. Two-dimensional (2D) images of the left ventricle were obtained both in long and 
short axes. Short axis recordings and M-mode tracings were performed at the level of the 
papillary muscles (Litwin et al., 1994). All of two-dimensional images, M-mode tracings and 
Doppler curves were recorded on videotape for later analysis.  
Fractional shortening (FS), in percent, was calculated according to the following formula: 
FS = (LVDd – LVDs)/LVDd x 100% 
where LVDd is left ventricular diameter in diastole, and LVDs is left ventricular diameter in 
systole according to the M-mode tracing from the cross-sectional view. All measurements were 
averaged for 3 consecutive cardiac cycles and were analyzed by an observer who was blinded to 
the treatment status of the animals. 
 
 
 
 
 
 
 
 
  
 
Figure O. Setup for the echocardiographic measurements performed by Dr. Tilo Burkardt (Zurich)  
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9. Histological and immunohistochemical study 
Rats were sacrificed with intravenous injection of potassium chloride (2 ml KCl 15%) at the 
level of the femoral vein, in order to stop the heart in diastole. Hearts were rapidly excised, the 
cardiac cavities were rinsed with PBS to remove blood and thrombus, then the hearts were fixed 
with 10% formalin for 24 hours. Afterwards, the hearts were cut into 3 parts parallel to the 
atrioventricular groove before being dehydrated and embedded in paraffin. Blocks containing the 
sections in contact with the cardiac patch were cut into 3 μm thickness slices and stained with 
hematoxylin and eosin. Consecutive sections were used for the immunohistochemical study. For 
the VEGF conditions, 3 in 60 sections were stained with anti-CD31 and 1 in 60 sections was 
stained with anti-α−smooth muscle actin (SMA) to detect the vessels. For the EPCs-gels 
transplanted hearts, 3 in 180 sections were stained with anti-CD31, every tenth of 180 sections 
were stained with anti-human CD34 and Tra-1-85 to detect the transplanted human cells.  
 
9.1 Antibodies 
All the used antibodies are summarized in the following table: 
Table C. List of Antibodies used for immunohistochemistry 
Antibody Antigen Recognized Dilution Incubation time Source 
sc-1506 Human and rat CD31 (PECAM) 1:150 Overnight Santa Cruz, Switzerland 
SMA Human and rat α−smooth muscle actin 1:250 1 hour 
gift of Pathology Dept., CMU, 
Switzerland 
M7165 Human CD34 1:50 1 hour M7165, DAKO, Denmark 
TRA-1-85 Human Tra-1-85 1:200 1 hour 
Developmental Studies 
Hybridoma Bank, United 
Kingdom 
 
The anti-CD31 antibody enabled to identify both human and rat endothelial cells within the 
vessels. Anti-SMA stained all the bigger vessels covered by a smooth muscle layer. Anti-human 
CD34 was designed to recognize the human EPCs or endothelial cells (ECs) derived from human 
EPCs, while anti Tra-1-85 marked any kind of human cells if present in the rat hearts.  
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9.2 Immunohistochemistry procedure   
The standard deparaffinization protocol was used, tissue slices were serially rehydrated in 
100%, 95%, 70% ethanol and di-distilled water. Endogenous peroxidase activity was blocked by 
1% H2O2 and the antigens were retrieved in a microwave for 5 minutes, 3 times in pH=6.0, 
10mM TP citrate solution. Non-specific binding was blocked with 10% serum (horse serum for 
anti-mouse second antibody and rabbit serum for anti-goat second antibody) for another 15 
minutes. Then the slices were incubated with the following prime antibodies: goat polyclonal 
anti-CD31/PECAM-1 (1:100, overnight at 4 ˚C), mouse monoclonal anti-SMA (1:250, 1 hour at 
room temperature), mouse monoclonal anti-hCD34 (1:50, 1 hour at room temperature) and 
monoclonal mouse anti-human TRA-1-85 (1:200, 1 hour at room temperature). Afterwards, the 
slices were incubated for 30 minutes at room temperature with one of the two following 
biotinylated secondary antibodies: rabbit anti-goat IgG (H+L) (1:100, Vector, BA-9500) and 
horse anti–mouse IgG (H+L) affinity purified and rat adsorbed (1:100, Vector, BA-2001) 
followed by another 30 minutes incubation in avidin-biotin solution (1:100, Vector, Vectastin 
ABC Kit) also at room temperature. All the incubations were preceded by thorough rinsing with 
PBS. The reaction products (brown) were visualized with 3, 3’-Diaminobenzidine 
tetrahydrochloride Dehydrate (DAB) and 3% hydrogen peroxide. Afterwards, the slices were 
washed with distilled water, counter staining was performed with hematoxylin for 1 minute 
except the slices stained with CD31. Negative controls were processed simultaneously using the 
same protocol, except that the primary antibodies were replaced by the dilution solution (PBS 
with 0.1 % Triton X-100). The stained slices were observed with ZEISS Axioskop 2 Plus photo 
microscope, images were captured and stored in digital tiff file format for later image analysis.  
 
 
10. Methods for the measurement of cardiac vessels  
 
10.1 Sampling method  
10.1.1 Sampling method for VEGF study  
3 in 60 sections per heart were stained with anti-CD31 and 9 or 12 photos (Figure P) were 
taken per section at a magnification of 200X. 
For the non-infarcted hearts, we first defined three zones: under the gel, at the border of the 
gel, and far from the gel and 3 pictures per zone were taken as illustrated in Fig. P a).  
Subsequently, we decided to simplify the sampling and to consider only 2 zones: under and 
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border of the gel, i.e. near the gel and far from the gel, i.e. in the septum, as indicated in Fig. P b). 
We took six photos per zone. Similarly, for the infarcted hearts, 6 pictures were randomly taken 
in two newly-defined zones, i.e. in the ischemic border zone of the infarct (near the gel) and in 
the septum (Fig. P c)).  
 
 
Figure P. Illustration of the method for the choice of the zones where 3 or 6 pictures were taken for the 
evaluation of the vessel number (non-infarcted rats (a and b) and infarcted rats (c) (anti-CD31 staining).  
Three zones (under the gel, at the border of the gel, and far from the gel) were first chosen, and 3 
pictures/zone were sampled (a). Subsequently, in non-infarcted hearts (b) and in infarcted hearts (c), two 
zones were defined and 6 pictures/zone were sampled:  near the gel (b) or at the border zone of the 
ischemic area (c), and in the septum (b and c).  
 
 
10.1.2 Sampling method for EPC study 
As for the EPCs study, we used the same sampling, i.e. 3 CD31- stained sections per heart 
and chose the simplified method: 1 zone per section was chosen (near the gel in the non-
infarcted hearts and in the ischemic border zone of the infarct in the infarcted hearts) and 6 
pictures per zone were taken (Fig. Q).
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Figure Q. Illustration of the method for the choice of the zones in non-infarcted rats (a) and infarcted rats 
(b) (anti-CD31 staining). (a) 6 pictures were randomly taken at the area near the gel. (b) 6 pictures were 
taken in the ischemic border zone of the infarct (near the gel). 
 
 
 
10.2 Method for vascular measurements  
 
10.2.1 Computer-assisted morphometric measurement of vessels   
Quantitative morphometric analysis was carried out in a blinded manner using a routine 
created in Metamorph Software (Version 6.1). 
 For vascular measurements, three parameters were determined: (1) total vessel density (total 
vessel number per mm2 of total tissue area), (2) ratio of total vessel number to myocardial area 
(total vessel number per mm2 of myocardial area) and (3) percentage of total vessel area (total 
vessel area per total tissue area, %).  Total tissue area was defined as the total image area minus 
the interstitial space (white empty space), to exclude a bias due to differences in the occurrence 
of interstitial space (either natural or artifactual, for instance tissue laceration during processing). 
Then, myocardial area was defined as total tissue area minus total vessel area.  
To assess which kind of vessel VEGF could promote, vessels were directly assigned by the 
Metamorph Software to one of three groups: 1) capillaries (vessel diameter < 10 μm), 2) 
microvessels (10μm ≤ vessel diameter ≤ 20 μm) and 3) macrovessels (vessel diameter > 20 
μm), as illustrated in Fig. R. 
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Figure R. Illustration of Macrovessels, Microvessels, capillaries and interstitial spaces (anti-CD31 
staining). 
The computer routine allowed performing the measurement of capillary density, microvessel 
density and macrovessel density. Each parameter was first expressed in 3 different ways as 
following: 
A) capillary density  
a)  capillary number per mm2 of total tissue area 
b)  ratio of capillary number to myocardial area (capillary number per mm2 of myocardial 
area) 
c)  percentage of capillary area (capillary area per total tissue area, %); 
 
B) microvessel density 
a) microvessel number per mm2 total area 
b) ratio of microvessel number to myocardium area (microvessel number per mm2 of 
myocardial area) 
c) percentage of microvessel area (microvessel area per total tissue area, %);  
 
C) macrovessel density 
a) macrovessel number per mm2 of total tissue area 
b) ratio of macrovessel number to myocardial area (macrovessel number per mm2 of 
myocardial area) 
c) percentage of macrovessel area (macrovessel area per total tissue area, %). 
 
By comparison of the three different ways of expression for the vessel density, we found that 
these three ways gave the very similar results, i.e. vessel density (vessel number per mm2 of total 
tissue area) could represent the ratio of vessel number to myocardial area and percentage of 
vessel area, we then chose the vessel density to be the parameter for measurement of the vessels. 
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interstitial space  
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10.2.2 Visual determination of the artery number 
Since α−smooth muscle actin (SMA) can also be contained in the veins, the count of SMA(+) 
vessels as the number of arteries would lead to an overestimation. We therefore decided to count 
the number of the arteries with a magnification of 100x by distinguishing them by their standard 
histologic features (Rendell et al., 1999). Typically, arteries and arterioles were identified by the 
presence of the characteristic layers: the endothelium, the internal elastic membrane, the tunica 
media consisting of one or more smooth muscle layers, and the tunica adventitia. In contrast, 
veins and venules were differentiated from arterioles by their large lumen diameter in relation to 
wall thickness, the much thinner smooth muscle layer, and the less substantial tunica adventitia 
(see Fig. S). The entire left ventricle was examined for the arterial presence. Artery density was 
expressed as artery number per mm2 of tissue area. 
 
Figure S. Immunohistochemical profile of arteries, arterioles, veins and venules stained by CD31. 
Arteries and arterioles were identified by the presence of the characteristic layers: the endothelium, the 
internal elastic membrane, the tunica media consisting of one or more smooth muscle layers, and the 
tunica adventitia. Veins and venules were differentiated from arterioles by their large lumen diameter in 
relation to wall thickness, the much thinner smooth muscle layer, and the less substantial tunica 
adventitia. 
 
11. Statistical analysis 
Statistical analysis was performed with both Statistica and Stata release 8.2 packages. Results 
are expressed as mean ± standard deviation (S.D.). The normality of the parameters’ distribution 
was verified with a skewness and kurtosis tests before and after applying usual transformations 
to normalize non-Gaussian variables by taking the square root transformation. Differences 
between groups were tested for statistical significance by one-way analysis of variance 
(ANOVA) and Student’s t-test when the groups were independent. As multiple observations 
were performed in each rat, we took into account the clustering of the observation during the 
subsequent regression analysis and applied an ANOVA with a repeated measure design, both 
techniques taking into account the fact that the observation are not independent within the same 
rat. Difference were considered significant at P<0.05. 
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F. RESULTS 
 
1. Angiogenic effect of VEGF121 covalently bound to fibrin cardiac patches  
 
1.1 Macroscopic examination  
We first analyzed the effect of VEGF-engineered gels engrafted on rat left ventricles. To rule 
out the possibility that VEGF administrated at too high concentrations could increase the 
vascular permeability leading to leakiness and causing pericardial or pleural effusion, we 
examined the chest cavity surrounding the hearts upon their excision and did not see any sign of 
effusion neither in the chest nor in the pericardium. Some loose connective tissue was usually 
present between the heart and the chest, but no difference was found between the rats with 
VEGF gels and the rats with empty fibrin gels. Fig. 1 depicts the macroscopic view of the 
explanted hearts.  
 
 
 
Figure 1. Macroscopic examination of the hearts. a, b were non-infarcted hearts with gels; c, d were 
infarcted hearts with gels. b, d were hearts cut parallel to the atrioventricular groove. The black arrows 
depict the loose connective tissues, the red arrows depict the suture for fixing the gels and the white arrow 
depicts the suture for the ligation. 
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1.2 Histological and immunohistochemical study 
Fig. 2 depicts H&E staining of heart sections. Compared to non-engrafted hearts (Fig. 2a), 
hearts engrafted with fibrin gels for 4 weeks, whether normal (Fig.2b) or infracted (Fig. 2c), 
displayed some loose connective tissues, possibly due to the suture or the operation. Otherwise, 
no significant differences could be found between the non-infarcted hearts with fibrin gels 
engraftment (Fig. 2b) and without gels engraftment (Fig.2a). 
 
Figure 2. H&E Staining showing non-infarcted heart without engraftment (a), non-infarcted heart with 
gel (b), and infarcted heart with gel (c). Black arrows show the loose connective tissues. 
 
 
As depicted in Fig. 3, heart structures observed by H&E staining had a relatively normal 
morphology, and no hemangioma or vessel malformations were found. We observed slightly 
more loose connective tissue containing signs of an active neovascularization near the infarct 
area as compared to non-infarcted hearts, but this was not apparently different in rats receiving 
VEGF gels as compared to rats with empty gels. This observation remains to be quantified.   
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Figure 3. H&E Staining of heart sections. Panels a, c, e depict non-infarcted hearts, and panels b, d, f 
infarcted hearts. No hemangioma or vessel malformations were found. Red arrows indicate suture for gel 
positioning onto the left ventricle; black arrows point to the neo-vessels in the loose connective tissue. 
 
 
Smooth muscle cells layering either the arteries or the big veins were stained with α−smooth 
muscle actin (SMA) antibodies and appeared colored in brown, as illustrated in Fig. 4. 
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Figure 4. Immunodetection of smooth muscle cells using anti-α-smooth muscle actin (SMA) antibodies. 
Panels a, c, e depict non-infarcted hearts; b, d, f depict infarcted hearts. No hemangioma or vessel 
malformations were found. Black arrows point the arteries, the red arrow indicates a vein layered with a 
reduced amount of smooth muscle cells in the vessel wall. 
 
 
Since SMA could not recognize the capillaries which have no smooth muscle, we used anti-
CD31 which stains the endothelial cells in order to recognize all types of vessels (Fig. 5).  
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Figure 5. CD31 Staining. a, c, e depict non-infarcted hearts, b, d, f depict infarcted hearts. No 
hemangioma or vessel malformations were found. The black arrow points a macrovessel, the red arrow 
depicts a microvessel, blue arrows depict the capillaries. 
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1.3 Effect of VEGF on myocardial vessel number 
First, we compared the total vessel density, the ratio of total vessel number to myocardial 
area, and the percentage of total vessel area in the three sampling areas (under the gel, at the 
border of the gel and far from the gel). In 5 non-infarcted rats (3 with VEGF gels, 2 with empty 
gels), no significant difference was found for these three parameters measured in the three 
sampling areas, and this was the case for either the VEGF-gel group or the empty-gel group (Fig. 
6 a, b, c).  
                        
 
Figure 6. Effect of VEGF on vessel number. a) Percentage of total vessel area, b) total vessel density, and 
c) Ratio of total vessel number to myocardial area in the three sampling areas (under the gel, at the border 
of the gel and far from the gel). No significant difference was found among the three sampling areas 
either in the VEGF-gel group or in the empty-gel group, however, a trend for a higher percentage of total 
vessel area, total vessel density, and ratio of total vessel number to myocardial area in VEGF-gel group 
(N=3) than in empty-gel group (N=2) was observed (3 sections per heart, 3 zones per section, and 3 
pictures per zone; mean±SD). 
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Then, we compared the same parameters between the VEGF-gel group and the empty-gel 
group respectively in the three sampling areas (under the gel, at the border of the gel and far 
from the gel). We observed a trend for an increased number of vessels in the VEGF-gel group 
but the difference was not statistically significant.  
However, when we combined the three sampling areas together, significant discrepancies in 
percentage of total vessel area (ANOVA F(2,59)=3.46; p<0.05) were observed between treated 
animals. Indeed, animals that received VEGF-fibrin gels had a significantly higher percentage of 
total vessel area than those with empty gels (p<0.05) (Fig. 6a). The differences in percentage of 
total vessel area were closely correlated to differences in total vessel density: here the statistical 
significance was even higher (ANOVA F(2,59)=6; p<0.005) (Fig. 6b) and animals exposed to 
VEGF also had a significantly higher ratio of total vessel number to myocardial area than those 
receiving empty gels (p<0.005) (Fig. 6c). 
 
Since we did not see any significant difference among the three sampling areas (under the 
gel, at the border of the gel and far from the gel), we changed the sampling method to two zones 
(near the gel and in the septum, see Fig. P in Material and Methods), and took 6 instead of 3 
images per zone. Given that the three parameters (vessel density, ratio of vessel number to 
myocardial area, and percentage of vessel area) gave very similar results, we used vessel density 
to perform all the vascular measurements. 
Fig. 7, 8 depict representative photos of the ventricular tissue stained by anti-CD31 antibody 
in non-infarcted hearts and infarcted hearts. 
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Figure 7. Immunohistochemical staining of ventricular vessels in non-infarcted hearts using anti-CD31 
antibody. Panels a and b: non-infarcted heart with VEGF-gels, panels c and d: with empty fibrin gels, 
panels e and f: normal heart without gel; panels a, c and e: area near the gel, panels b, d and f: area within 
the septum. 
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Figure 8. Immunohistochemical staining of ventricular vessels in infarcted hearts using anti-CD31 
antibody. Panels a and b: VEGF-gels, panels c and d: empty fibrin gels; panels a and c: area at the 
ischemic border of the infarct (near the gel), panels b and d: area within the septum. 
 
• Evaluation of total vessel density 
Fig. 9 illustrates the comparison of the total vessel density measured in VEGF-gel group (3 
non-infarcted and 3 infarcted rats) to the total vessel density scored in empty-gel (2 non-infarcted 
and 3 infarcted rats) or no-gel group (3 non-infarcted rats). In the non-infarcted hearts (Fig. 9a), 
first of all, there was no significant difference between the rats with empty gel and the rats 
without gel. Moreover, no significant difference was found between near the gel and in the 
septum either in the VEGF-gel group or in the empty gel group and the group without gel. Total 
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vessel density was significantly higher in the VEGF-gel group than in the empty-gel or no-gel 
groups. In the infarcted rats (Fig. 9b), the total vessel density was significantly higher in the 
VEGF-gel group than in the empty gel group, and such difference was even more significant at 
the area near the gel than in the septum. Importantly, the total vessel density was significantly 
higher at the area near the gel than in the septum in the VEGF-gel group, and no such significant 
difference was found in the empty-gel group. No significant difference of total vessel density 
was found between non-infarcted rats and infarcted rats, implanted with empty or VEGF gels.  
 
 
 
Figure 9. Effect of VEGF on the total vessel density in non-infarcted rat hearts (a) and infarcted rat hearts 
(b). In the non-infarcted rat hearts (a), total vessel density was significantly higher in the VEGF-gel group 
(N=3) than in the empty gel group (N=2) or no-gel group (N=3). No significant difference was found 
between the empty gel group and no-gel group. In the infarcted rats (b), the total vessel density was 
significantly higher in the VEGF-gel group (N=3) than in the empty gel group (N=3), and such difference 
was even more significant at the area near the gel than in the septum. Total vessel density in the VEGF-
gel group was significantly higher at the area near the gel than in the septum, while no such significant 
difference was found in the empty gel group. (3 sections per heart, 2 zones per section, and 6 pictures per 
zone; All P values computed with ANOVA models (without repeated measure design) and Bonferroni 
correction: * P< 0.05, **P<0.01, ***P< 0.001; mean ± SD). 
 
Since the total vessel density was not normally distributed, we were able to normalize it 
using the square root transform, namely getting a Gaussian distribution. As 36 observations were 
performed in each rat (3 sections, 2 zones, 6 pictures by zone), we took into account the 
clustering of the observation during the subsequent regression analysis and applied an ANOVA 
with a repeated measure design, both techniques taking into account the fact that the 
observations are not independent within the same rat.     
Considering all the groups together and using multiple regression, we predicted the square 
root of total vessel density from 3 independent variables: infarct (no or yes), localization of the 
sample (septum: no or yes) and treatment group (without treatment, empty-                   
gel, VEGF-gel) and their respective interactions. The resulting model explained 25% of the 
variance in the square root of total vessel density, with none of the interaction terms being 
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significant, and only one main effect remaining significant: the total vessel density in the VEGF-
gel group being significantly higher than in both empty gel group (p=0.004) and without 
treatment group (p=0.010). 
We then compared the square root of total vessel density among the subgroups by ANOVA, 
taking into account that repeated observations were performed on the same rats. Fig. 10 shows 
that a significant difference was found only between the VEGF-gel and empty-gel group in the 
area near the gel in the infarcted rats (Fig 10b).   
 
 
Figure 10. Square root of total vessel density in non-infarcted rat hearts (a) and infarcted rat hearts (b). A 
significant difference was only scored in the VEGF-gel group as compared to the empty gel group in the 
area near the gel, within the infarcted rats (3 sections per heart, 2 zones per section, and 6 pictures per 
zone; All P values computed with ANOVA models with a repeated measure design: **P<0.01, mean ± 
SD). 
 
However, statistical significance was found in the differences among the VEGF-gel, empty 
gel and without treatment groups in the area near the gel for the non-infarcted rats when using 
multiple regression analysis (P=0.030) (Fig. 10a, left bars, condition “near the gel”).  
Considering all the 6 subgroups together (Fig. 10a) for the non-infarcted hearts, square root 
of total vessel density analyzed by ANOVA shows a significant group effect (P=0.0057), but no 
zone effect and no interaction of zone with group. It was significantly higher in the VEGF-gel 
group than in the empty gel group (P=0.0206) or the group without treatments (P=0.0026). 
Again, the empty-gel group and the group without treatment were not different (Fig.10a, grey 
and white bars). 
 
To investigate which kind(s) of vessel(s) VEGF could promote, we classified vessels by 
Metamorph Software analysis into the following three groups: (1) capillaries (vessel diameter < 
10 μm), (2) microvessels (10μm ≤ vessel diameter ≤ 20 μm) and (3) macrovessels (vessel 
diameter > 20 μm). We calculated the following parameters: capillary density, microvessel 
density and macrovessel density.   
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• Evaluation of capillary density 
Fig. 11 shows that the capillary density in non-infarcted (a) and infarcted (b) rat hearts was 
significantly higher in the VEGF-gel group than in the empty gel group. While in non-infarcted 
hearts, no difference was observed between the areas near the gel and in the septum, regardless 
of the treatment, in infarcted rats, the capillary density in the VEGF-gel group was significantly 
higher near the gel as compared to the septum. Differences between non-infarcted and infarcted 
heart were not significant, neither in the VEGF-gel group nor in empty gel group. 
 
 
 
Figure 11. Effect of VEGF on capillary density in non-infarcted rat hearts (a) and infarcted rat hearts (b). 
Capillary density was significantly higher in the rats with VEGF-gels than in the rats with empty gels 
either in the non-infarcted hearts or in the infarcted hearts. Moreover, in the infarcted rats, the capillary 
density in the presence of VEGF was significantly higher near the gel than in the septum. (3 sections per 
heart, 2 zones per section, and 6 pictures per zone; All P values computed with ANOVA models (without 
repeated measure design) and Bonferroni correction: * P< 0.05, **P<0.01, ***P< 0.001; mean ± SD). 
 
 
We then normalized the capillary density by calculating its square root (sqrt) (as described 
above) (see Fig. 12). Using multiple regression (with rats clustering), we predicted the square 
root of capillary density from 3 independent variables: infarct (no or yes), localization of the 
sample (septum: no or yes) and treatment group (empty gel or VEGF-gel) and their respective 
interactions. The resulting model explained 24% of the variance in the square root of capillary 
density, with none of the interaction terms being significant and only one main effect being 
significant: sqrt of capillary density in the VEGF-gel group being significantly higher than in 
empty gel group (Fig. 12a and b, p=0.003). 
We compared the sqrt of capillary density among the subgroups by ANOVA, taking into 
account that repeated observations were performed on the same rats. Only the difference 
between the VEGF-gel group and empty gel group in the area near the gel was significant in 
infarcted rat hearts (Fig. 12b).   
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Figure 12. Effect of VEGF on the square root of capillary density in non-infarcted rat hearts (a) and 
infarcted rat hearts (b). Square root of capillary density in the infarcted rat hearts was significantly higher 
in the VEGF-gel group than in empty gel group in the near the gel area (3 sections per heart, 2 zones per 
section, and 6 pictures per zone; All P values computed with ANOVA models with a repeated measure 
design: **P<0.01, mean ± SD). 
 
Multiple regression analysis did not detect significant difference between the VEGF-gel 
group and the empty gel group in the area near the gel in the non-infarcted rat hearts. 
Again considering all the 6 subgroups together (Fig. 12a) for the non-infarcted hearts, square 
root of capillary density analyzed by ANOVA was significant higher in the VEGF-gel group 
than in the empty gel group (P=0.0228, Fig. 12a) but no zone effect and no interaction of zone 
with group were observed. 
 
 
• Evaluation of microvessel and macrovessel density 
The distribution of both microvessel and macrovessel density was not normalizable. Using 
multiple regression, we predicted the microvessel density from 3 independent variables: infarct 
(no or yes), localization of the sample (septum: no or yes) and treatment group (empty gel or 
VEGF-gel) and their respective interactions. As indicated in Fig. 13, the resulting model 
explained 22% of the variance in the microvessel density, with none of the main effects or their 
interaction terms being significant (the P value for the difference between the VEGF-gel group 
and the empty gel group was 0.068). Once again, the ANOVA analysis revealed no significant 
difference between VEGF-gel group and empty gel group either in the non-infarcted rats 
(P=0.6217, Fig. 13a) or in the infarcted rats (P=0.1332, Fig. 13b). 
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Figure 13. Effect of VEGF of the microvessel density in non-infarcted rat hearts (a) and infarcted rat 
hearts (b). No significant difference was found between VEGF-gel group and empty gel group 
either in the non-infarcted rats (P=0.6217) or in the infarcted rats (P=0.1332) (3 sections per heart, 
2 zones per section, and 6 pictures per zone; mean ± SD).  
 
For the macrovessel density, we used the same multiple regression model. The model 
explained 18% of the variance, with none of the interaction terms being significant except one 
main effect: macrovessel density in the VEGF-gel group was significantly higher than empty gel 
group (p=0.021) (Fig. 14). When the macrovessel density among the subgroups was analyzed by 
ANOVA, no significant difference was found between VEGF-gel group and empty gel group 
either in the non-infarcted rats (P=0.0586, Fig. 14a) or in the infarcted rats (P=0.2481, Fig. 14b).   
 
 
Figure 14. Effect of VEGF on macrovessel density in non-infarcted (a) and infarcted rat hearts (b). No 
significant difference was found between VEGF-gel group and empty gel group either in the non-
infarcted rats (P=0.0586) or in the infarcted rats (P=0.2481) (3 sections per heart, 2 zones per section, and 
6 pictures per zone; mean ± SD). 
 
• Evaluation of artery  density 
Since the measured macrovessels included both arteries and veins and we judged the 
sampling of 6 images per zone not sufficient to prevent a bias on the result interpretation, we 
scored the number of arteries in the whole left ventricle in 3 of 60 sections per heart. Fig. 15 
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shows no significant difference in the artery density between the VEGF-gel group and the empty 
gel group either in the non-infarcted (Fig. 15a) or in the infarcted (Fig. 15b) rat hearts. 
 
 
 
Figure 15. Effect of VEGF on the artery density in the whole left ventricle in non-infarcted hearts (a) and 
infarcted hearts (b). No significant difference was found between the rats with VEGF-gels and the rats 
with empty gels (3 sections per heart; mean ± SD).  
 
1.4 Evaluation of left ventricular function by echocardiography 
The echocardiography was performed before animal sacrifice and cardiac function was 
assessed according to the parameters measured on the M-mode tracing. Table 1 showed the 
difference of cardiac parameters such as LVDs, LVDd and FS between the VEGF-gel group (3 
non-infarcted rats and 2 infarcted rats) and the empty gel group (2 non-infarcted rats and 3 
infarcted rats) in non-infarcted (A) and infarcted (B) rat hearts.  
  
Table 1.  Effect of VEGF on the left ventricular function in non-infarcted and infarcted rat 
hearts (mean ± SD) 
 
A. Non infarcted hearts (N=5) 
 VEGF-gel (N=3) Empty gel (N=2)  P value 
LVDs (mm) 3.95 ± 0.22 3.26 ± 0.48 0.2361 
LVDd (mm) 7.10 ± 0.35 6.39 ± 0.59 0.0833 
FS (%) 44.32 ± 3.14 49.07 ± 2.85 0.2482 
B. Infarcted hearts (N=5) 
 VEGF-gel (N=2) Empty gel (N=3)  P value 
LVDs (mm) 2.24 ± 0.91 4.43 ± 1.07 0.0833 
LVDd (mm) 4.51 ± 1.43 7.54 ± 0.14 0.0833 
FS (%) 51.20 ± 4.77 41.38 ± 13.21 0.2482 
 
No significant difference was found between the VEGF-gel group and empty-gel group in the 
non-infarcted rats, but in the infarcted rats, a pronounced trend to have better heart function in 
the VEGF-group was detected even though it was not statistically significant. To get the 
significance, more rats are needed.  
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2. Transplantation of EPCs-seeded fibrin gels 
2.1 Macroscopic examination 
Fig. 16 depicts the macroscopic views of 2 of 20 rat hearts implanted with EPC-seeded gels. 
Upon explantation, we observed some loose connective tissue between the heart and the chest, 
but apparently no difference was found between the rats with EPCs gels and with empty fibrin 
gels. 
 
Figure 16. Macroscopic examination of the hearts implanted with EPCs-seeded gels. Panels a, b: non-
infarcted hearts; panel c, d: infarcted hearts. In panels b, d, hearts are cut parallel to the atrioventricular 
groove. The black arrows indicate connective tissues, the red arrow depicts the suture fixing the gels, 
while the blue arrow indicates the position of the infarct. 
 
2.2 Histological and immunohistochemical study 
We performed 180 sections in the proximity of the gel area and 1 every 10 were stained by 
H&E. Heart structure engrafted with either EPCs- or empty-gels were indistinguishable and 
relatively normal, with no visible hemangioma, vessel malformations or tumors, as illustrated in 
Fig. 17,18 and 19. 
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Figure 17. H&E Staining of non-infarcted hearts engrafted with EPCs-seeded gels for 3 weeks (panels a, 
c, e, N=3) or for 8 weeks (panels b, d, f, N=4). 
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Figure 18. H&E staining of infarcted hearts engrafted with EPC-seeded gels immediately after LAD 
ligation. Panels a, c, e: 3 weeks after engraftment, N=3; panels b, d, f: 8 weeks after engraftment, N=3. 
 
 
 
 
 
 61
 
 
 
Figure 19. H&E staining of infarcted hearts engrafted with EPC-seeded gels 1 week after LAD ligation. 
Panels a, c, e: 3 weeks after engraftment, N=4; panels b, d, f: 8 weeks after engraftment, N=3. 
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To detect the transplanted human EPCs or their progenies (ECs derived from human EPCs) 
in the rat hearts, we first used anti-human CD34 antibody. As shown in Fig. 20, CD34 marker 
worked nicely as positive control in human placenta sections.  
 
 
 
Figure 20. Anti-human CD34 staining in human placenta (b), arrows depict the stained endothelial cells 
of the vessels in placenta. (a) depicts the negative control (without first antibody).  
 
 
However, we were not able to retrieve CD34-positive cells in the rat hearts transplanted with 
EPCs-gels. Fig. 21 shows the immunohistochemical staining using anti-human CD34 antibody in 
non-infarcted as well as infarcted hearts. 
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Figure 21. Anti-human CD34 staining of rat hearts engrafted with EPC-seeded gels. Non infarcted hearts 
were examined 3 weeks (a, N=3) or 8 weeks (b, N=4) after engraftment. Infarcted hearts were engrafted 
either immediately after LAD ligation and examined 3 weeks (c, N=3) or 8 weeks (d, N=3) later, or 
engrafted 1 week after ligation and examined 3 (e, N=4) or 8 weeks (f, N=3) later.  
 
Given that no human CD34 (+) cells were ever found in any of the transplanted rats, we 
checked this antibody on EPCs-gels embedded for immunohistochemical examination. 
Surprisingly, EPCs were negative for anti-human CD34 antibody (Fig. 22). 
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Figure 22. Anti-human CD34 immunochemical staining of EPCs seeded on fibrin gels. Sections were 
incubated without (a) or with (b) the first antibody (anti-human CD34). 
 
This could be explained by the following hypothesis: the EPCs lose the CD34 marker after 
the 7 days of in vitro culture and/or the subsequent in vivo engraftment. To verify this, we chose 
another marker, the Tra-1-85 which is present on the surface of all human cells. We therefore 
first tested the anti-Tra-1-85 antibody on human placenta and on EPC-seeded fibrin gels. As 
shown in Fig. 23, both placenta and EPCs in vitro were positively stained. 
 
       
Figure 23. Tra-1-85 staining of placenta (a, b) and EPC-seeded fibrin gels (c, d). Panels a, c are negative 
control (without first antibody). Arrows depict the positive staining. 
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We then used Tra-1-85 to detect the transplanted human EPCs or their progenies (EPC-
derived ECs) in the EPCs-gel transplanted rat hearts. Unfortunately, no Tra-1-85-positive cells 
were detected (Fig. 24) in 1 every 10 sections examined over a total 180 sections.  
 
 
 
Figure 24. Tra-1-85 staining of the rat hearts. Panels a, b were non-infarcted hearts, analyzed after 3 (a, 
N=3) or 8 weeks (b, N=4) after engraftment. Infarcted hearts were engrafted either immediately after 
LAD ligation and examined 3 weeks (c, N=3) or 8 weeks (d, N=3) later, or engrafted 1 week after ligation 
and examined 3 (e, N=4) or 8 weeks (f, N=3) later. 
 66
2.3 ISH Study 
Given that no positive result was obtained by immunohistochemical examination, we tried 
preliminarily a technique of in situ hybridization (ISH) to identify human cells. ISH can detect 
Alu sequences in the human nuclei (stained in blue). This technique was performed by Dr. Paola 
Bonfanti, our collaborator at the Laboratory of Dynamic Stem Cells (LDCS) in EPFL in 
Lausanne. In a first trial, we did not find any human cells in the 3-4 sections examined (Fig. 25). 
 
  
Figure 25. In situ hybridization technique (ISH) for the detection of human cells in the rat heart. (a) 
human placenta, red arrows depict alu sequences revealed in blue within the nuclei by ISH. (b) rat heart 
section, negative for alu sequences. 
 
 
 
2.4 Vascular measurements 
Despite the lack of human EPC retrieval in the engrafted hearts, we decided to assess 
whether the transplanted EPCs had somehow an angiogenesis effect in the rat hearts. Total tissue 
area, total vessel and capillary number as well as their density were measured (Fig. 26). No 
significant differences were found either between the rats with EPCs-gels and the rats with 
empty gels or among the different EPCs-gel groups. 
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Figure 26. Effect of EPC-seeded gel engraftment on the total vessel density (A) and on capillary density 
(B) within the left ventricles. E3, non-infarcted hearts engrafted with EPCs-gels for 3 weeks  (N=3); E8, 
non-infarcted hearts engrafted with EPCs-gels for 8 weeks  (N=4); L0E3, infarcted hearts transplanted 
with EPCs-gels immediately after ligation for 3 weeks  (N=3); L0E8, infarcted hearts transplanted with 
EPCs-gels immediately after ligation for 8 weeks (N=3); L1E3, infarcted hearts transplanted with EPCs-
gels 1 week after ligation and examined 3 weeks later (N=4); L1E8, infarcted hearts transplanted with 
EPCs-gels 1 week after ligation and examined 8 weeks later (N=3). As control, rats were transplanted 
with empty gels for each respective condition. No significant differences were found among the groups (3 
sections per heart, 1 zone per section, 6 pictures per zone; mean ± SD). 
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2.5 Evaluation of left ventricular function after EPC engraftment 
Table 2 shows the cardiac parameters (LVDs, LVDd and FS) in EPCs-gel groups and control 
groups.  
 
Table 2. Comparison of left ventricular function in EPCs-gel groups and control groups 
 
Group N LVDs (mm) LVDd (mm) FS (%) 
Without treatment 1 0.36 0.68 47.06 
E3 1 0.31 0.71 57.28 
G3 0 - - - 
E8 1 0.29 0.60 51.09 
G8 1 0.29 0.60 51.09 
L0E3 3 0.58 ± 0.053 0.82 ± 0.062 29.65 ± 11.54 
L0G3 3 0.44 ± 0.107 0.75 ± 0.014 41.38 ± 13.21 
L0E8 3 0.49 ± 0.118 0.78 ± 0.031 36.79 ± 12.57 
L0G8 0 - - - 
L1E3 4 0.59 ± 0.139 0.87 ± 0.089 32.18 ± 9.08 
L1G3 0 - - - 
L1E8 0 - - - 
L1G8 0 - -- - 
 
L0: engraftment immediately after LAD ligation; L1: engraftment 1 week after LAD ligation. E3 
and E8 indicate EPC-engrafted hearts examined 3 and 8 weeks later, respectively. G3 and G8 
indicate empty gel-engrafted hearts examined 3 and 8 weeks later, respectively. 
 
 
Since there were not enough non-infarcted rats for the statistical analysis, we compared only 
the infarcted rats engrafted with empty or EPC-seeded gels. Using ANOVA analysis, there was 
no significant difference among all the groups (L0E3, L0G3, L0E8, L1E3) (P=0.612). 
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G. DISCUSSION 
 
In this thesis, we studied two strategies of therapeutic neovascularization for the regeneration 
of the heart in a rat model of myocardial infarction:  1) the delivery of VEGF covalently bound 
to fibrin gel matrices to the left ventricular myocardium, and 2) cell therapy by transplanting 
CD133-selected putative EPCs using tissue-engineered matrices. We used fibrin-based hydrogels 
as vehicles to provide VEGF or CD133-selected putative EPCs to infarcted or non-infarcted 
hearts and to investigate whether such kind of therapy could promote the neovascularization of 
the left ventricle in the rat model of myocardial infarction. 
 
1. Delivery of VEGF covalently bound to fibrin cardiac patches 
 
We explored the angiogenic effect of VEGF by implanting fibrin gel matrices covalently 
bounded with VEGF on the rat hearts (either infarcted or non-infarcted). As shown in Fig. 9, 
fibrin-immobilized VEGF could significantly increase the total vessel density compared to the 
empty gel groups both in the non-infarcted rats and in the infarcted rats. However, when taking 
into account the fact that the observations are not independent within the same rat (36 
observations repeated in each rat) and applying an ANOVA analysis with a repeated measure 
design, significant difference was found between VEGF-gel and the empty gel group only in the 
area near the gel in the infarcted left ventricle (Fig. 10b). However, when using multiple 
regression analysis, significant differences were found between the VEGF-gel group and empty 
gel group in the area near the gel both for the non-infarcted hearts (Fig. 10a) and the infarcted 
hearts (Fig. 10b).  
Therefore, the angiogenic effect of VEGF was found in the area near the gel both in the non-
infarcted hearts and infarcted hearts, with more pronounced effect in the ischemic border of the 
infarct. Possible explanations for such results include the following: (1) since the endogenous 
production of VEGF is upregulated in ischemic tissues (Banai et al., 1994; Hashimoto et al., 
1994), and the potency of VEGF is mainly due to paracrine and autocrine effects (Syed et al., 
2004), when activated under hypoxic conditions, the autocrine loop serves to amplify and 
protract the response in endothelial cells stimulated by exogenously administered VEGF (Syed et 
al., 2004); (2) as the endothelial cells proliferate in response to hypoxia (Syed et al., 2004), the 
ECs in the ischemic part might be more efficient to utilize the angiogenic factors. 
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In the attempt to identify which kind(s) of the vessels VEGF could promote, we observed 
that only capillaries were significantly increased with the most pronounced effects found in the 
ischemic part of the infarcted rat hearts (Fig. 11, 12). This is in accordance to the VEGF 
biological function, i.e. a specific endothelial-cell mitogen, essential for the initial stages of 
blood vessel formation, and a potent factor for endothelial cell proliferation, migration and 
survival (Ferrara and Davis-Smyth, 1997; Carmeliet et al., 1996). 
There was a trend, although not yet significant, to have more microvessels in the VEGF-gel 
group. In fact, the time point chosen (4 weeks) was probably too short to expect a strong 
significant effect, and more time is needed to consolidate such an effect. Observations at longer 
time points, such as at 2 months, are therefore required to confirm the maintenance and/or the 
improvement of VEGF effect on microvessel formation. 
There was also a trend to have more macrovessels in the VEGF-gel group, but we should be 
careful when interpreting such results. Indeed, the fact that only few macrovessels were scored in 
each image, this could constitute a bias, due also to the limited number of images taken. 
We did not observe a VEGF effect on the arteries in our experimental conditions. 
Nevertheless, Siddiqui et al and Springer et al have both reported that VEGF could also promote 
the arteriogenesis in mice (Siddiqui et al., 2003; Springer et al., 2003). The study of Siddiqui et 
al demonstrated that myocardial arteriogenesis could be stimulated by transient overexpression 
of VEGF-A after 10 days. In addition to capillary growth, the VEGF effect on arterioles, 
especially small ones, was more pronounced in the ischemic post-infarction myocardium. This 
indicated that VEGF may play a direct role in accumulation of the smooth muscle cells via their 
VEGF receptors (Ishida et al., 2001). A possible arteriogenic effect of VEGF should be 
investigated in the future. 
In our study, we did not find any hemangioma or vessel malformations in the rat hearts, as 
instead reported by others (Lee et al., 2000; Schwarz et al., 2000). This indicated that, in our 
experimental conditions, the local sustained cell-demanded release of VEGF has no deleterious 
effect, but efficiently promote neoangiogenesis at the capillary level. Moreover, our controlled 
release of VEGF through fibrin gel translated the high overall dose of VEGF into a low local 
dose at any point in time, according to the cellular demand. In support of this concept, recent 
studies demonstrated that the microenvironmental amount of VEGF, but not its total dose, 
determines whether VEGF-induced angiogenesis becomes normal or aberrant (Ozawa et al., 
2004).  
As shown by Keshet and colleagues (Dor et al., 2003), the endogenous VEGF protein level is 
not sufficient to sustain all vessels generated under conditions of VEGF overexpression. Thus, 
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withdrawal of the exogenous VEGF source resulted in selective regression of newly formed, yet 
immature, vessels devoid of stably associated periendothelial cells by way of disaggregation and 
apoptosis (Dor et al., 2003). Nevertheless, our findings indicate that exogenous VEGF alone, 
when released slowly in low and sustained dose, may induce “stable” vessels, given that the 
angiogenic effect of VEGF has lasted for 4 weeks in our study.  
At this point, it is important to underline the fact that other growth factors like angiopoietin 1, 
ephrin-B2, platelet-derived growth factor BB (PDGF-BB) have important roles in stabilizing the 
newly formed capillaries and promoting the arteriogenesis (Oike et al., 2002; Benjamin et al., 
1998; Suri et al., 1996). Indeed, administration of mixed growth factors with complementary 
activities, e.g. VEGF plus angiopoietin 1 (Siddiqui et al., 2003), or VEGF plus PDGF 
(Richardson et al., 2001), might be more effective in producing a stable vasculature, as 
compared to a single VEGF administration. 
An other strategy to multiple factor administration, could be the administration of genes 
encoding one of the hypoxia inducible factors (HIF-1β, ΗΙF−1α, and HIF-2α), which are not in 
itself angiogenic, but stimulate the expression of multiple genes (Semenza, 1998). Hypoxia 
inducible factors are transcription factors which, as their name implies, are activated by low 
oxygen tension. Once activated, they bind to the promoters of multiple genes and thereby 
stimulate gene expression. Genes that they stimulate include VEGF, VEGFR1, VEGFR2, Ang-2, 
Tie-1, and nitric oxide synthase, which are thought to be involved in the homeostatic responses 
to hypoxia and cause an optimal angiogenesis response (Epstein et al., 2001). 
An alternative strategy could also be the delivery of cells with the capacity to express 
multiple angiogenic factors in appropriate sequence and concentration. One type of cellular 
approach is the monocyte (Arras et al., 1998), which, upon phenotypic differentiation to a tissue 
macrophage, expresses such potential angiogenic factors as VEGF, nitric oxide, MCP-1, and 
various cytokines. However, a special attention should be paid to the role of cytokines and 
inflammatory cells to the evolution of the damaged tissue, favoring their positive effects and 
avoid possible deleterious actions. 
Our results using empty fibrin gels show that there was no difference in the total vessel 
density between the hearts with empty gels and the hearts with no treatment. This indicates that, 
while empty fibrin gels alone cannot indirectly promote angiogenesis, as suggested in the case of 
fibrin glue (Dvorak et al., 1987), they do not have deleterious effect per se. Even though some 
loose connective tissue could be detected at the gel implantation site, fibrosis was not found by 
H&E staining (collagen staining will be done to prove this). Moreover, the loose connective 
tissue might be caused by the incision of the pericardium and the thoracotomy or the suture, 
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since we could also see such connective tissue on the hearts operated (injection in the 
myocardium or LAD ligation) but not engrafted with fibrin gel (data not shown). No such 
connective tissue was detected in a non-infarcted rat heart with empty gel for 8 weeks (data not 
shown). 
Since we did not see any fibrin gel left by microscopic examination at the end of 3 or 4 
weeks, we assume that the fibrin gel has been totally degraded or adsorbed. We plan to perform 
fibrin staining to assess the eventual residual presence of fibrin and to measure how long it takes 
for complete fibrin degradation. 
It has been shown that delivery of angiogenic factors by systemic infusion through veins is 
not effective (Sato et al., 2001). Repeat administrations of VEGF induce VEGF receptor 
tachyphylaxis (Lopez et al., 1997), direct injection into the myocardium would be instead 
preferable, although this way of administration may disturb the normal heart structure, which is 
essential for the ventricular electrical activity and contraction. By consequence, the attachment 
of a degradable fibrin gel to the epicardium could be, in our view, much safer and less 
destructive. Through small (4-5 cm) thoracotomy (Rosengart et al., 1999) or thoracoscopy (Lei 
et al., 2004), as well as through the diaphragm, delivery of the angiogenic factors by fibrin gel 
matrices might be feasible for the clinical treatment of the patients.  
The vessel density in the infarct zone was not measurable due to the tissue destruction. 
Therefore, the promotion of angiogenesis would be more beneficial in the ischemic peripheral 
tissue than in the infarct part, which ultimately evolves into a scar.  
By comparing the left ventricular function (FS), we can see that infarcted rats with empty 
fibrin gel have a lower FS compared to infarcted rats with VEGF-gels. Despite a lack of 
significance, a trend for a better cardiac function was nevertheless detectable in the VEGF-gel 
group. This difference would reach statistical significance by including more rats in the group. 
 
 
2. Transplantation of EPCs-seeded fibrin gels 
 
Upon aging or in some pathological conditions, such as type 2 diabetes, the ability of 
endothelial proliferation and EPCs mobilization is weakened or impaired. As a result, it is 
appealing to provide exogenous EPCs which could differentiate into ECs in situ and could thus 
promote neovascularization of the myocardium.  
Human EPCs have been isolated from peripheral blood and expanded in vitro (Asahara et al., 
1997). The transplantation (by direct injection in the muscle) of human EPCs has been shown to 
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facilitate successful salvage of ischemic hindlimb and to improve blood perfusion in ischemic 
limbs of nude mice (Kalka et al., 2000). Moreover, EPCs may also trans-differentiate into 
beating cardiomyocytes (Condorelli et al., 2001).  
We addressed the question whether the delivery of EPCs through the application of EPCs-
seeded gels could improve the myocardial function by inducing new vessel formation. This in 
vivo study of EPCs was designed for the first time to investigate whether CD133-selected 
putative EPCs delivered by fibrin gel matrices could differentiate into endothelial cell in situ and 
incorporate into the neovessels in the non-infarcted and infarcted rat hearts.   
At this point of our analysis, we cold not find EPCs positive for the CD34 marker both in the 
gels in vitro and in the heart sections analyzed (18 colored for a total of 180 sections per heart 
(1/10)). However, CD34 was present on the EPCs before seeding in the gels (as seen by 
immunofluorescence, Dr. P. Zammaretti communication, in press). Whether the CD133-positive 
EPCs lose the CD34 antigen or never acquire it upon in vitro culture or in vivo engraftment, this 
remains to be investigated. 
To circumvent this problem we used the antibody Tra-1-85, able to detect all kinds of human 
cells in the rat heart. Indeed our EPCs were positive for this marker. However, we were not able 
to find positive cells in the sections examined (18 stained for a total of 180 sections per heart 
(1/10)). 
To rule out the possibility that such antigen was not retrievable by immunochemical study, 
probably due to over fixation of the antigens (24 hrs in formalin for the rat hearts vs. 15 mins in 
PFA for the gels), we preliminarily tried an ISH technique able to stain human nuclei by 
detecting Alu sequences. Preliminary staining indicated a strong labeling in our controls: 
placenta and EPC-seeded gels. Few heart sections tested did not permit to conclude on the 
possible presence or absence of EPCs. However, ISH is a technique of choice for future analysis. 
Since EPCs may release a variety of growth factors that act in a paracrine manner and 
contribute to the profound angiogenic effect (Urbich et al., 2003), we explored the angiogenic 
effect of the transplanted EPCs in the rat hearts by comparing the total vessel density and 
capillary density between the EPCs group and controls. No significant difference was detected 
either among the different EPCs groups or between them and their respective controls (see figure 
26). 
We then examined the left ventricular function by echocardiography. No improved cardiac 
function could be detected in the EPC group compared to rats treated with empty fibrin gels. 
One possibility is that the transplanted EPCs did not survive and/or did not brought 
prolonged benefit to the treated rat hearts. This might be due to the following reasons: 
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(1) the putative EPCs used in this study being derived from short term culture (classical 
fractionation methods), only a small cellular subset may eventually possess 
angioblast-like characteristics (Gulati et al., 2003);   
(2) the amount of EPCs (106 per gel)  is not sufficient to give benefit effect; 
(3) the immunosuppression by CsA might not be sufficient for preventing the rejection of 
the human EPCs by the rat immunologic system, in our earlier studies of  
transplantation of mouse embryonic stem cells (ESCs) to rat, this same 
immunosuppression strategy was working well. Human to rat transplantation 
tolerance remains to be addressed. 
(4) the structure of the fibrin gel is not ideal for the transplantation of the EPCs. 
 
At this point, we should be careful to draw final conclusions due to the following considerations: 
(1) the fixation conditions of the hearts (24 hrs) may reveal inappropriate for the 
preservation of the Tra-1-85 human marker.  
(2) A bigger sampling of the section stainings should performed in order to completely 
exclude the presence of surviving EPCs. 
(3) More animals should be included in the analysis in order to show or disprove the 
statistical difference in the measured cardiac parameter. 
 
All together, the possibility to provide cells, such as EPCs or cardiac cells, in the ischemic 
area via the use of biomatrices in order to promote tissue regeneration is an important question 
that has to be pursued and optimized. More work should be done to improve the procedure of 
transplanting EPCs, like providing angiogenic factors together with the EPCs transplantation to 
increase the possibility for the EPCs survival. Moreover, modification of EPCs through VEGF 
gene transfer can enhance EPC proliferation, adhesion and incorporation into endothelial cell 
monolayers in vitro (Iwaguro et al., 2002). Such modified EPCs would also facilitate the strategy 
of cell transplantation to augment naturally impaired neovascularization in vivo. 
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H. CONCLUSIONS 
 
VEGF covalently immobilized in the fibrin gel could promote angiogenesis by increasing 
capillary formation in the non-infarcted and infarcted rat hearts, an effect more pronounced in 
the ischemic area of infarcted rat hearts. Our controlled sustained low dose release of VEGF 
prevented the formation of aberrant vessels. Infarcted rats with VEGF-gels have a trend to have 
better cardiac function compared to the rats with empty gels. Further studies with a higher 
number of rats are in process in order to show a significant impact of such strategy on the heart 
function. If the results presented in this work will be confirmed, fibrin gel matrices could 
constitute a future efficient vehicle for delivering angiogenic factors to the heart. 
Although our EPC results were not positive at this point, we will modify and improve our 
strategy of cell delivery through fibrin matrices and we are confident that such a cell delivery 
system will prove beneficial and effective in the future. 
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